HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 6.06 MAC1. 29NOV23:07:52:4129NOV23:07:52:41 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS ADSL_2 SASDATA 6.06 29NOV23:07:52:4129NOV23:07:52:41 Subject-Level Analysis Dataset HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000023400000000000000000000 STUDYID Study Identifier USUBJID Unique Subject Identifier SUBJID Subject Identifier for the Study SITEID Study Site Identifier &AGE Age BEST  *AGEU Age Units 2SEX Sex 7SEXN Sex (N) BEST  8) RACE Race @ RACEN Race (N) BEST  i ETHNIC Ethnicity q ETHNICN Ethnicity (N) BEST   RACIALD Racial Designation RACIALDNRacial Designation (N) BEST  COUNTRY Country SAFFL Safety Population Flag RANDFL Randomized Population Flag ENRLFL Enrolled Population Flag DTHFL Subject Death Flag ARM Description of Planned Arm  ARMCD Planned Arm Code ACTARM Description of Actual Arm  ACTARMCDActual Arm Code TRT01P Planned Treatment for Period 01 TRT01PN Planned Treatment for Period 01 (N) BEST   TRT02P Planned Treatment for Period 02 TRT02PN Planned Treatment for Period 02 (N) BEST  ,TRT01A Actual Treatment for Period 01 4TRT01AN Actual Treatment for Period 01 (N) BEST  OTRT02A Actual Treatment for Period 02 WTRT02AN Actual Treatment for Period 02 (N) BEST  r& TRTSEQP Planned Sequence of Treatments z&!TRTSEQA Actual Sequence of Treatments "BRTHDT Date of Birth #BRTHDTF Date of Birth Imput. Flag $DTHDTC Date/Time of Death %DTHDT Date of Death DATE  &DTHDTF Date of Death Imputation Flag 'RANDDT Date of Randomization DATE  (RANDNO Randomization Number )RFSTDT Subject Reference Start Date DATE  *RFSTTM Subject Reference Start Time TIME  +RFENDT Subject Reference End Date DATE  ,RFENTM Subject Reference End Time TIME  -RFPENDT Date of End of Participation DATE  .RFICDT Date of Informed Consent DATE   /TRTSDT Date of First Exposure to Treatment DATE  0TRTSTM Time of First Exposure to Treatment TIME  1TRTEDT Date of Last Exposure to Treatment DATE  %2TRTETM Time of Last Exposure to Treatment TIME  -3TR01SDT Date of First Exposure in Period 01 DATE  54TR01STM Time of First Exposure in Period 01 TIME  =5TR01EDT Date of Last Exposure in Period 01 DATE  E6TR01ETM Time of Last Exposure in Period 01 TIME  M7TR02SDT Date of First Exposure in Period 02 DATE  U8TR02STM Time of First Exposure in Period 02 TIME  ]9TR02EDT Date of Last Exposure in Period 02 DATE  e:TR02ETM Time of Last Exposure in Period 02 TIME  m;TRTSDTM Datetime of First Exposure to Treatment DATETIME uTR01EDTMDatetime of Last Exposure in Period 01 DATETIME ?TR02SDTMDatetime of First Exposure in Period 02 DATETIME @TR02EDTMDatetime of Last Exposure in Period 02 DATETIME AVAX101DTVaccination Date 01 DATE  BVAX102DTVaccination Date 02 DATE  CVAX201DTVaccination Date 03 DATE  DVAX202DTVaccination Date 04 DATE  EAGETR01 Age at Vaccination 01 BEST  FAGETRU01Age Units at Vaccination 01 GAGETR03 Age at Vaccination 03 BEST  HAGETRU03Age Units at Vaccination 03  IAGEGR1 Pooled Age Group 1 JAGEGR1N Pooled Age Group 1 (N) BEST  )KARACE Analysis Race LARACEN Analysis Race (N) BEST  MRACEGR1 Pooled Race Group 1 #NRACEGR1NPooled Race Group 1 (N) BEST  <OEOSDCDT End Of Study Discontinuation Date DATE  D$PEOSDCRS End Of Study Discontinuation Reason LQEOTDCDT End Of Treatment Discontinuation Date DATE  p$REOTDCRS End Of Treatment Discontinuation Reason xSTRTDELT Adjusted Treatment for Rel. Efficacy TTRTDELTNAdjusted Treatment for Rel. Efficacy (N)BEST  UEVASEFFLEvaluable Efficacy Pop Flag - Asympt VEVSCEFFLEvaluable Efficacy Pop Flag - Seroconv WEXCL17FLExclusion Flag 17 XINCL18FLNo PD prior to 1st N-Binding test PD2 YEXCL18FLExclusion Flag 18 ZEXCRIT18Exclusion Criterion 18 [INCL9FL Have valid immuno within timeframe 2 k\INCL17FLHave N-Binding result PD2 l]EXCL4FL Exclusion Flag 4 m^EXCL9FL Exclusion Flag 9 n_SURVICDTAsymptomatic Surveillance Consented DateDATE  o$`VAX202 Vaccination 04 waVAX10UDTVaccination Date Unplanned DATE  bVAX20UDTVaccination Date Unplanned in Period 02 DATE  $cVAX10U Vaccination Unplanned dVAX20U Vaccination Unplanned in Period 02 eVAX101TMVaccination Time 01 TIME  fVAX102TMVaccination Time 02 TIME  gVAX10UTMVaccination Time Unplanned TIME  hVAX201TMVaccination Time 03 TIME  iVAX202TMVaccination Time 04 TIME  jVAX20UTMVaccination Time Unplanned in Period 02 TIME  kINVID Investigator Identifier lINVNAM Investigator Name mDOSALVL Actual Dosing Level  nDOSPLVL Planned Dosing Level !oDOSPLVLNPlanned Dosing Level (N) BEST  "pDOSALVLNActual Dosing Level (N) BEST  *qREACTOFLReactogenicity Population Flag 2rCOHORT Cohort Group 3sCOHORTN Cohort Group (N) BEST  4tPHASEN Study Phase (N) BEST  <uPHASE Study Phase D vAGEGR2 Pooled Age Group 2 KwAGEGR3 Pooled Age Group 3 T xAGEGR4 Pooled Age Group 4 UyAGEGR4N Pooled Age Group 4 (N) BEST  `zAGEGR2N Pooled Age Group 2 (N) BEST  h{AGEGR3N Pooled Age Group 3 (N) BEST  p|AGETGR3 Age Group at Vaccination 03 x}AGETGR3NAge Group at Vaccination 03 (N) BEST  y$~VAX101 Vaccination 01 $VAX102 Vaccination 02 $VAX201 Vaccination 03 UNBLNDDTTreatment Unblinded Date DATE  REVXICDTRe-Informed Consent Date DATE  EOTXDCDTEnd Of Open Label Treatment D/C Date DATE  EOTXDCRSEnd Of Open Label Treatment D/C Reason  BMICAT Baseline BMI Category BMICATN Baseline BMI Category (N) BEST  'OBESEFL Obese Flag for Adolescent /COMBODFLFlag for Comorbodities 0NIGV1FL N-binding Antibody Neg at Visit 1 Flag 1NAATNFL NAAT Negative at Visit 1 Flag 2COVBLST Baseline SARS-CoV-2 Status 3V01DT Date of Unblinding or Visit at 1MPD2 DATE  6V02DT Date of Unblinding or Visit at 6MPD2 DATE  >V02OBDT Date of Dose 3 or Visit at 6MPD2 DATE  FV03DT Date of Visit at 1M after Vax3/4 DATE  NV04DT Date of Visit at 6M after Vax3/4 DATE  VV3C19NIGC19NIG Result at Visit 3 ^DVSTDT Start Date of Important PD DATE  aPOP1PDDTFirst PD date for safety DATE  iPOP2PDDTFirst PD date for efficacy DATE  qPOP3PDDTFirst PD date for immunogenicity DATE  yBLDV1FL Blood Sample Drawn before Vax 1 BLDV2FL Blood Sample Drawn 1 Week after Vax 1 BLDV3FL Blood Sample Drawn before Vax 2 BLDV4FL Blood Sample Drawn 1 Week after Vax 2 BLDV5FL Blood Sample Drawn 2 Weeks after Vax 2 BLDV6FL Blood Sample Drawn 1 Month after Vax 2 BLDV7FL Blood Sample Drawn 6 Months after Vax 2 BLDV1DT Blood Sample Date before Vax 1 DATE  BLDV2DT Blood Sample Date 1 Week after Vax 1 DATE  BLDV3ADTAdditional Bld Sample Date 3W after Vax1DATE  BLDV4ADTAdditional Bld Sample Date 4W after Vax1DATE  BLDV5ADTAdditional Bld Sample Date 5W after Vax1DATE  BLDV6ADTAdditional Bld Sample Date 7W after Vax1DATE  BLDV3DT Blood Sample Date before Vax 2 DATE  BLDV4DT Blood Sample Date 1 Week after Vax 2 DATE  BLDV5DT Blood Sample Date 2 Weeks after Vax 2 DATE  BLDV6DT Blood Sample Date 1 Month after Vax 2 DATE  BLDV7DT Blood Sample Date 6 Months after Vax 2 DATE  INCL1FL Are eligible for the study at rand INCL2FL Have received Vax 1 as randomized INCL3FL Have valid and DTM immuno result 1 INCL6FL No important PD determined by clinician INCL7FL Received 2 doses as rand within window INCL8FL Have valid and DTM immuno result 3 INCL10FLUnblinded after 1M post Dose 2 visit EXCL1FL Exclusion Flag 1 +EXCRIT1 Exclusion Criterion 1 EXCL2FL Exclusion Flag 2 $EXCRIT2 Exclusion Criterion 2 EXCL3FL Exclusion Flag 3 8EXCRIT3 Exclusion Criterion 3 9EXCRIT4 Exclusion Criterion 4 :EXCL6FL Exclusion Flag 6 ;EXCRIT6 Exclusion Criterion 6 <RSEXSAF Reason for Exclusion from Safety Pop EXCL7FL Exclusion Flag 7 EXCRIT7 Exclusion Criterion 7 EXCL8FL Exclusion Flag 8 kPEXCRIT8 Exclusion Criterion 8 lbEXCRIT9 Exclusion Criterion 9 EXCL10FLExclusion Flag 10 IEXCRIT10Exclusion Criterion 10 MEXCRIT17Exclusion Criterion 17 hAAI01FL Dose 1 all-available Immun Popu Flag AAI02FL Dose 2 all-available Immun Popu Flag EVALEFFLEvaluable Efficacy Popu Flag EV14EFFLEvaluable Efficacy Popu Flag - 14 days AAI1EFFLDose 1 all-available Efficacy Popu Flag AAI2EFFLDose 2 all-available Efficacy Popu Flag AAI2ASFLDose 2 all-available Asympt Popu Flag EVAL02FLDose 2 evaluable Immun Popu Flag INCL4FL Have valid immuno within timeframe 1 EVAL01FLDose 1 evaluable Immun Popu Flag SCREEN Screening DS3KFL FU to 6MPD2 DS30KFL Phase 3 30k Subjects Flag OPBOUFL Subjects Received Placebo & unblinded JPNFL Japanese Subject Flag PEDREAFLPhase 2/3 Pop for 12-25 Reacto Subset PEDIMMFLPop for Non-inferiority Assessement HIVFL HIV Positive Subjects Flag EV1MD2FLSubject without Evidence 1MPD2 BDCSRDT Double Blinded Follow-up Censor Date DATE  X1CSRDT Crossover Dose1 Censor Date DATE  STCSRDT Study Censor Date DATE  FUP2CUT PD2 FU Time in Days: to Cutoff BEST  FUP2UNB PD2 FU Time in Days: to Unblinding BEST  FPX1CUT Post Xover D1 FUTM in Days: to Cutoff BEST  FUNBCUT Unblinding FUTM in Days: to Cutoff BEST  FUP1CUT PD1 FU Time in Days: to Cutoff BEST  FUP1UNB PD1 FU Time in Days: to Unblinding BEST   FUP2CAT1PD2 FU Time Cat 1: to Cutoff FUP2CA1NPD2 FU Time Cat 1 (N): to Cutoff BEST   FUP2CAT2PD2 FU Time Cat 2: to Unblinding $FUP2CA2NPD2 FU Time Cat 2 (N): to Unblinding BEST  0 FPX1CAT1Post Xover D1 FUTM Cat 1: to Cutoff 8FPX1CA1NPost Xover D1 FUTM Cat 1 (N): to Cutoff BEST  B FUP1CAT1PD1 FU Time Cat 1: to Cutoff JFUP1CA1NPD1 FU Time Cat 1 (N): to Cutoff BEST  VRNACAT HIV RNA Category ^RNACATN HIV RNA Category (N) BEST  _CD4CAT CD4 Category for HIV-positive gCD4CATN CD4 Category for HIV-positive (N) BEST  hCOMPLDT Date of Completion DATE  pPD1POSDTPost-dose Positive Swab Result Date DATE  x HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 C4591001C4591001 1005 10051317100513171005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20158 DVDDW.DWDVDVDDVDDVDDVD....Hr^Hr|xHr^Hr|x..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Normal weightA NNYYNEGDVDWDW..NEG....YNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWCpBBqCB10-11 monthsA6-7 months Ap0-1 month A11-12 monthsA . ...C4591001C4591001 1005 10051328100513281005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20159 DVDDW.DWDVDVDDVDDVDDVD....Hr^Hr{Hr^Hr{..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW6 .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW6. Normal weightA NNYYNEGDVDWDW..NEG....YNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWCBBqCB10-11 monthsA6-7 months Ap0-1 month A11-12 monthsA . ...C4591001C4591001 1005 10051339100513391005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20160 DVDLDW.DWDVDVDLDWDLDVDLDVDDWDDWDLHr`HsLHr`Hr{Hsr|pHsLDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DLD.DDL.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDVDWDWDWDXeNEG....YNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBmBqCB10-11 monthsA6-7 months Ap3-4 monthsA@11-12 monthsA . ...C4591001C4591001 1005 10051410100514101005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20163 DVDDW.DWDVDVDDWD(DVDDWDdDWDҴDWD(HrHs(HrHrdHsu4Hs(DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW#BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDd.DҴD(.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW#DWDWDWDXeNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBlCB8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051412100514121005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22270 DVD DW.DWDVDVD DW DDVD DW D....Hr,Hr& Hr,Hr& ..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW0 .. D D....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW0. Obese A@YNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBmCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051413100514131005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22269 DVDDW.DWDVDVDDW DDVDDW D....Hr(HrHr(Hr..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW( .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWcDW(. Overweight A0YNYYNEGDW(DWbDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWbDWDWBBWBuBBl7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051414100514141005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22273 DVD DW.DWDVDVD DWDDVD DW DDWDDWDHrEHsHrEHrHs}"tHsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW(BNT162b2 (30 (*ESC*){unicode 03BC}g).. D D.DD.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW(DWDWDWDXuNEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBeBlCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051415100514151005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22274 DVDDW.DWDVDVDDWDڬDVDDW DDWDtDWDڬHrHs(,HrHr/HsvetHs(,DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DtDڬ.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW(DWDWDWDXfNEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBlCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051417100514171005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22785 DVDDW..DVDVDDWD DVDDWDDWDDWD HrHsFHrHrŅHsƶxHsFDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW7BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD .79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDX DXNEG....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB-B1CPB8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWiC4591001C4591001 1005 10051418100514181005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22786 DVDDW.DWDVDVDDWDDVDDWD....HrHHrņHrHHrņ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW7 .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW7. Normal weightA NYYYNEGDW1DWDW..NEG....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBB1CPB8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1005 10051419100514191005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22794 DVDLDW..DVDVDLDWTD(DVDLDW DDW?DDWTD(Hr%Hs"(Hr%HrHsf\Hs"(DVDW DW?DWTAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DLD.DD(.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW?. Normal weightA NNYYNEGDW(DW5DW>DWpDXNEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW5DWDWBB*BBCPB=8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1005 10051420100514201005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22792 DVDިDW.DWDVDVDިDW DDVDިDW D....Hr$(HrHr$(Hr..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW( .. DިD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW(. Underweight ANNYYNEGDW(DWDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051421100514211005AYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23097 DVD0DW.DWDVDVD0DWDӤDVD0DWD$DWD DWDӤHru0HsϤHru0Hr!Hss HsϤDVDWDWDWAYEARSAYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. D0D$.D DӤ.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW/DWDWDWDXeNEG....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BlBqC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051422100514221005AYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23098 DVDDW.DWDVDVDDWDhDVDDWDDWDHDWDhHrwHshHrwHr"XHssHHshDVDWDWDWAYEARSAYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDW/BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DHDh.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW/DWDWDWDXeNEG....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BlBqC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051424100514241005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23100 DVDDW.DWDVDVDDWDDDVDDWDD....HroHrDHroHrD..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW3 .. DDD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW3. Underweight ANNYYNEGDW3DWDW..NEG....YNNNNYYDV........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBB^C0B8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1005 10051425100514251005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23101 DVDDW.DWDVDVDDWDDVDDWD....HrLHrCHrLHrC..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW0 .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW0. Normal weightA NYYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051427100514271005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23589 DVDDDW.DWDVDVDDDWDDVDDDWDDWD@DWDHrzDHsHrzDHr%PHsrYHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW+BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDD.D@D.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW/DWDWDWDXcNEG....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBzBmBqCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051428100514281005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23596 DVD͌DW.DWDVDVD͌DWD|DVD͌DWD|....HrHrβHrHrβ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW1 .. D͌D|....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW1. Normal weightA NNYYNEGDW1DWDW..NEG....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB~BkCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051429100514291005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23597 DVD DW.DWDVDVD DWDDVD DWD....Hr Hrq@Hr Hrq@..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW6 .. D D....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW6. Underweight ANNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051430100514301005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23600 DVD{DW.DWDVDVD{DWDDVD{DWD4DWxDDWDHr@HslHr@Hrm4HsQ<HslDVDWDWxDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. D{D4.DD.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWuDWx. Normal weightA NNYYNEGDW0DWtDWwDWDXJNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWtDWDWBBaBBBBv8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1005 10051431100514311005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23890 DVDDW.DWDVDVDDWDDVDDWD....HrpHr̈́HrpHr̈́..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW0 .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW0. Obese A@YNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBByBqBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051436100514361005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23897 DVDDW.DWDVDVDDWDʼDVDDWDʼ....HrXHrͨHrXHrͨ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW6 .. DDʼ....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW6. Underweight ANNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB~BlBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051437100514371005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23894 DVDpDW.DWDVDVDpDWDDVDpDWDDWD@DWDHrHs!HrHrͨHsjHs!DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD.D@D.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW6DWDWDWDXmNEG....YNNNNYNDV........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BcBlBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051438100514381005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23892 DVDDW.DWDVDVDDWDDVDDWD͌DWDDWDHrLHs!HrLHrͫHsjHHs!DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW6BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD͌.DD.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW6DWDWDWDXmNEG....YNNNNYNDV........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BcBlBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051439100514391005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV24039 DVDԔDW.DWDVDVDԔDWDDVDԔDWD....HrHrb|HrHrb|..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW0 .. DԔD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW0. Normal weightA NNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB~BmBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1005 10051440100514401005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24041 DVDHDW.DWDVDVDHDWDhDVDHDWD DWDDWDhHrHshHrHraHst<HshDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DHD .DDh.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW0DWDWDWDXeNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BkBmBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051441100514411005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV24034 DVDDW.DWDVDVDDWD(DVDDWD(....HrpHrͦ(HrpHrͦ(..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW1 .. DD(....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW1. Overweight A0NNYYNEGDW1DWDW..NEG....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBOBB7-8 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1005 10051444100514441005AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24043 DVDdDW..DVDVDdDWD0DVDdDWDDWDDWD0HrHs~@HrHrͷHsvtHs~@DVDWDWDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DdD.DD0.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW0DWDWDWDXfNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BjBlBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1005 10051445100514451005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24130 DVDDW.DWDVDVDDWD~DVDDWDTDWDDWD~Hr8HsLHr8HrzTHs~HsLDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW0BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDT.DD~.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW0DWDWDWDXlNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BdBlBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWbC4591001C4591001 1005 10051447100514471005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24134 DWDDW.DWDWDWDDW(DDDWDDW(DD....Hr$`HrDHr$`HrD..DWDW(..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWD .. DDD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWD. Overweight A0NNYYNEGDWDDWDW..NEG....YNNNNYYDW........DWDDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBjBlBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051448100514481005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24138 DWDDW.DWDWDWDDWDDWDDW(DDWDDWDHrCHsHrCHrHs~HsDWDW(DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDDWDWDWDXlNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBiBdBmBB~7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1005 10051449100514491005AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24137 DWDDW.DWDWDWDDW(DDWDDW(D....Hr@HrۜHr@Hrۜ..DWDW(..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0NNYYNEGDWDDWDW..NEG....YNNNNYYDW........DWDDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBiBmBB~7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1005 10051450100514501005AYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW26654 DWDшDW.DWDWDWDшDWDDWDшDW(DPDWD<DWDHr^HsmxHr^HrPHs{<HsmxDWDW(DWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWDBNT162b2 (30 (*ESC*){unicode 03BC}g).. DшDP.D<D.79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDDWDWDWDXjNEG....YNNNNYNDW........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBjBfBlBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1005 10051451100514511005AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26655 DWD`DW.DWDWDWD`DW*DDWD`DW*D....Hrͪ`HrHrͪ`Hr..DWDW*..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWF .. D`D....79828 Davis, Matthew Gilruth ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWF. Underweight ANYYYNEGDWFDWDW..NEG....YNNNNYYDW........DWFDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBBB7-8 months A6-7 months Ap0-1 month A8-9 months A . ...C4591001C4591001 1006 10061183100611831006AYEARSMAMULTIPLE A`HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20339 DVD0DW.DWDVDVD0DWDDVD0DWDDWDDWDHrHs,HrHr̐Hsv/Hs,DVDWDWDWAYEARSAYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D0D.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNYYNEGDW0DWDWDWDXdNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBlCPB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061184100611841006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20340 DVDtDW.DWDVDVDtDVDDVDtDVD....HrHrxHrHrx..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWp .. DtD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWp. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWCBBXCPB9-10 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1006 10061188100611881006AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20341 DVDDW.DWDVDVDDWDDVDDVDDWDDWDHrsHsHHrsHr) HssHsHDVDVDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDXcNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBpC@B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061189100611891006AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20348 DVDDW.DWDVDVDDVDDVDDVD....HrsHrTHrsHrT..DVDV..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBqC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ..DWUC4591001C4591001 1006 10061190100611901006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20638 DVD|DW.DWDVDVD|DVDDVD|DVD....HrM0Hr8HrM0Hr8..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. D|D....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Overweight A0NNNYPOSDWDWDW..POS....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBlC0B9-10 months A5-6 months A`0-1 month A9-10 months A . ..DWzC4591001C4591001 1006 10061191100611911006AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20640 DVDDW.DWDVDVDDVDDVDDVD....HrmLHr$HrmLHr$..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWL .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWL. Normal weightA NYYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlC0B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061196100611961006AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20644 DVD DW.DWDVDVD DWDtDVD DVDDWDDWDtHr͠HsSHr͠HrԼHsuPHsSDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. D D.DDt.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDXdNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBkBlC0B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061200100612001006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20647 DVDҴDW.DWDVDVDҴDWiDDVDҴDWD4DWSDLDWiDHrHs=pHrHr`Hs Hs=pDVDWDWSDWiAYEARSBYEARS12-15 YearsAWHITE AWHITE ADWLOST TO FOLLOW-UP . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DҴD4.DLD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWFDWS. Overweight A0NNYYNEGDW$DWEDWRDWDX&NEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWEDWDWBBEBBCBZ8-9 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1006 10061201100612011006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20867 DVDxDW.DWDVDVDxDWDpDVDxDWDp....HrxHr`HrxHr`..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DxDp....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0YNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlC B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061203100612031006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20871 DVDXDW.DWDVDVDXDVD8DVDXDVD8....HrXHr׸HrXHr׸..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWS .. DXD8....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWS. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBdC B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061206100612061006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20872 DVDPDW.DWDVDVDPDWDDDVDPDWDD....HrHrDHrHrD..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DPDD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDWDWDW..POS....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBABB5-6 months A`5-6 months A`0-1 month A5-6 months A` . ..DW C4591001C4591001 1006 10061207100612071006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20874 DVDDW.DWDVDVDDWDDVDDWD....Hr HrHr Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Underweight ANYYYNEGDWDWDW..POS....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBABB5-6 months A`5-6 months A`0-1 month A5-6 months A` . ..DWC4591001C4591001 1006 10061209100612091006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20998 DVDDW.DWDVDVDDWDDVDDWD....Hr\HrHr\Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Normal weightA NNNNPOSDW"DWDW..POS....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWDWBBBlCB9-10 months A5-6 months A`0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061212100612121006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20999 DVDʀDW.DWDVDVDʀDWD<DVDʀDWDDWD(DWD<Hr>HsmHr>HrHss(HsmDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DʀD.D(D<.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDXdNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWDWBBBlBmCB9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061213100612131006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21000 DVDDDW.DWDVDVDDDWDDVDDDWD....Hr=Hr Hr=Hr ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DDD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBmCB9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061214100612141006AYEARSMABLACK OR AFRICAN AMERICAN A HISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21001 DVDߘDW.DWDVDVDߘDWDՄDVDߘDWDڬDWDDWDՄHrSHsHrSHrZHssݤHsDVDWDWDWAYEARSAYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DߘDڬ.DDՄ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDWDWDWDWDXqNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBqCB9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ..DWxC4591001C4591001 1006 10061219100612191006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21141 DVDtDW.DWDVDVDtDWD$DVDtDWDDWDHDWD$HrtHsHrtHrSHsoHHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANN Y NY YDWbBNT162b2 (30 (*ESC*){unicode 03BC}g).. DtD.DHD$.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW!DWDWDWDXNEG....YNNNNYNDV........DW!.YY YNNY Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWDWDWBBBPBPCB9-10 months A6-7 months Ap2-3 monthsA09-10 months A . ..DW~C4591001C4591001 1006 10061220100612201006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21143 DVD8DW..DVDVD8DWDDVD8DWD....Hr8HrHr8Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D8D....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW7.. Normal weightA NNYYNEGDW%DW6DW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW6DWDWBB2BCBG8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1006 10061221100612211006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21147 DVDDW.DWDVDVDDWDDVDDWD....HrHr4HrHr4..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Normal weightA NNYYNEGDW%DWDW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBMBB7-8 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1006 10061223100612231006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21152 DVDDW.DWDVDVDDWDDDVDDWDDWD{ DWDDHr*HsGHr*Hr|Hsr$HsGDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D{ DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANYYYNEGDW)DWDWDWDXdNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061224100612241006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21261 DVDHDW.DWDVDVDHDWDHDVDHDWDH....Hr=HHrHr=HHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWb .. DHDH....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWb. Overweight A0NNYYNEGDW%DWDW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061226100612261006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21262 DVDDW.DWDVDVDDWDDVDDWDDWD$DWDHrOHs@HrOHr \HsnT$Hs@DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D$D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW!DWDWDWDX`NEG....YNNNNYNDV........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBqCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061227100612271006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21264 DVDDW.DWDVDVDDWDDVDDWD....HrPHr HrPHr ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW!DWDW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061228100612281006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21267 DVDDW.DWDVDVDDWD4DVDDWDHDWD$DWD4HrS@Hs/HrS@Hr/HHsnT$Hs/DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDH.D$D4.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW$DWDWDWDX`NEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBqCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061229100612291006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21442 DVDDW.DWDVDVDDWNDDVDDWD$DW9DDWNDHrpPHs=HrpPHr$HrhHs=DVDWDW9DWNAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD$.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW9. Normal weightA NNYYNEGDW(DW5DW8DWjDX NEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWDWBB0BBCBE8-9 months A1-2 months A 7-8 monthsA9-10 months A . ...C4591001C4591001 1006 10061230100612301006AYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21446 DVDDW.DWDVDVDDWD0DVDDWD0....HrpHr0HrpHr0..DVDW..AYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD0....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYNPOSDW)DWDW..POS....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWDWBBBjCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061231100612311006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21448 DVDDW.DWDVDVDDWDDVDDWD....HrLHr<HrLHr<..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061232100612321006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21450 DVD0DW.DWDVDVD0DWDDVD0DWDDWD@DWDHrHs<HrHrgHss@Hs<DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D0D.D@D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW#DWDWDWDXdNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061233100612331006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21561 DVDDW.DWDVDVDDWDDVDDWDDWD|DWDHrHsxHrHrgHss|HsxDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D|D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW#DWDWDWDXdNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061234100612341006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21563 DVD~TDW.DWDVDVD~TDWD}(DVD~TDWD}(....HrTHr7HrTHr7..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. D~TD}(....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Underweight ANNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBmCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061235100612351006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21568 DVD~DW.DWDVDVD~DWD~DVD~DWD}dDWDɐDWD~HrHs)HrHr7HsuHs)DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D~D}d.DɐD~.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW#DWDWDWDXdNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBmCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061236100612361006AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21571 DVD`DW.DWDVDVD`DWDȠDVD`DWDȠ....Hr`Hr Hr`Hr ..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. D`DȠ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW!DWDW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061237100612371006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21696 DVDDW..DVDVDDWD\DVDDWDDWD DWD\HrHsHrHrlHsn HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D D\.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDX^NEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBqCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061239100612391006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21699 DVDDW.DWDVDVDDWDDVDDWDDWD`DWDHrHsHrHre HsrHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D`D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDXeNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061241100612411006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21702 DVDDW..DVDVDDWDDVDDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW] .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW]. Normal weightA NNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061242100612421006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21704 DVDDW.DWDVDVDDWD~TDVDDWD~T....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW[ .. DD~T....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW[. Underweight ANNYYNEGDW%DWDW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1006 10061243100612431006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21864 DVDDDW..DVDVDDDWD~TDVDDDWD~T....HrHrTHrHrT..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. DDD~T....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Normal weightA NNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061244100612441006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21865 DVDDW.DWDVDVDDWD DVDDWD ....HrHr HrHr ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWY .. DD ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWY. Normal weightA NNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061245100612451006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21869 DVDTDW.DWDVDVDTDWDhDVDTDWD\DWDDWDhHrHshHrHr \HssHshDVDWDWDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DTD\.DDh.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW"DWDWDWDXeNEG....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBmCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061247100612471006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21871 DVE@DW.DWDVDVE@DWDLDVE@DWDDWD`DWDLHr^HsSHr^Hr`Hsn`HsSDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. E@D.D`DL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW$DWDWDWDX` ....YNNNNNNDV..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBpBpCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061248100612481006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22046 DVD$DW.DWDVDVD$DWDDVD$DWDDWDDWDHr/$HsHr/$HrMtHstHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D$D.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW%DWDWDWDXeNEG....YNNNNYNDV........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWDWBBBkBmCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061249100612491006AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22047 DVDDW.DWDVDVDDWDDVDDWD....HrHHrHrHHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Obese A@YNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBmCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061250100612501006AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22050 DVDdDW.DWDVDVDdDWDDVDdDWDDWDPDWDHrIdHs HrIdHrHsv PHs DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DdD.DPD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW+DWDWDWDXxNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBmCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061252100612521006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22051 DVDDW.DWDVDVDDWDDDVDDWDD....Hr`HrDHr`HrD..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW] .. DDD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW]. Underweight ANNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061253100612531006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22173 DVDdDW.DWDVDVDdDWDDVDdDWD DWD~DWDHrvdHsCPHrvdHr]Hsr'HsCPDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DdD .D~D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW(DWDWDWDXdNEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061254100612541006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22174 DVDDW.DWDVDVDDWDtDVDDWDt....HrrHrHrrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. DDt....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Obese A@YNYYNEGDW)DWDW.. ....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061256100612561006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22176 DVDDW.DWDVDVDDWD\DVDDWD\....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWZ .. DD\....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWZ. Overweight A0NNYYNEGDW(DWDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWZC4591001C4591001 1006 10061257100612571006AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22182 DVDDWk..DVDVDDWODŔDVDDWDDW:D\DWODŔHrHslHrHr|Hr\HslDVDWDW:DWOAYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D\DŔ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW:. Normal weightA NNYYNEGDW$DW5DW9DWkDX NEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWDWBB/BBCBB8-9 months A1-2 months A 7-8 monthsA9-10 months A . ...C4591001C4591001 1006 10061258100612581006AYEARSMANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPNOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22296 DVDDW.DWDVDVDDW D}DVDDW D}....Hr$Hr!\Hr$Hr!\..DVDW ..AYEARS. 12-15 YearsANATIVE HAWAIIAN OR OTHER PACIFIC ISLANDERAPALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DD}....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Normal weightA NNYYNEGDW/DWDW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061259100612591006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22300 DVDxDW.DWDVDVDxDWoDlDVDxDW DDWVDDWoDlHr8HsEZHr8Hr3,Hs$hHsEZDVDW DWVDWoAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DxD.DDl.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW@DWV. Underweight ANNYYNEGDW)DW?DWUDWDX,POS....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW?DWDWBB3BBCpBI8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ..DWC4591001C4591001 1006 10061260100612601006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22302 DVDDW.DWDVDVDDWD8DVDDW DDWDDWD8Hr9pHs8Hr9pHr3hHsr14Hs8DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD8.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW)DWDWDWDXcNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBmBpCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061261100612611006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22303 DVD DW.DWDVDVD DW D$DVD DW D$....HrHr3HrHr3..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. D D$....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Underweight ANNYYNEGDW)DWDW..NEG....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBmCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061262100612621006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22426 DVDpDW.DWDVDVDpDWD\DVDpDWD<DWDDWD\HrHsz\HrHr<Hs}.hHsz\DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD<.DD\.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW0DWDWDWDXNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBeBpCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061263100612631006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22428 DVDDW.DWDVDVDDW D\DVDDW D\....HrHr@\HrHr@\..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DD\....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Underweight ANNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBlCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061264100612641006AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22429 DVD DW.DWDVDVD DW DDVD DW D....HrHrHHrHrH..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. D D....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Overweight A0YNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061265100612651006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23313 DVDDW.DWDVDVDDWD{ DVDDWD{ ....Hru Hrp Hru Hrp ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWNO LONGER MEETS ELIGIBILITY CRITERIA. BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW] .. DD{ ....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW]. Underweight ANYYYNEGDW+DWDW..NEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNYYNYDWDWDWBBABB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061266100612661006AYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22433 DVD4DWp..DVDVD4DWTDtDVD4DWDdDW?DDWTDtHr4Hs!tHr4HrŐdHs-hHs!tDVDWDW?DWTAYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D4Dd.DDt.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW>DW?. Overweight A0NNYYNEGDW1DW=DW>DWpDXPOS....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDW=DWDWBB0BBC`BF8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ..DW#C4591001C4591001 1006 10061267100612671006AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22558 DVDDW..DVDVDDWDݸDVDDWDDWDpDWDݸHrHs8HrHrڜHsSpHs8DVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DpDݸ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW:DWDWDX DXPOS....YNNNNYNDV........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBB,B,C`B8-9 months A6-7 months Ap1-2 monthsA 9-10 months A . ..DWC4591001C4591001 1006 10061269100612691006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22561 DVDDW.DWDVDVDDWDDVDDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW[ .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW[. Underweight ANNYYNEGDW1DWDW.. ....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBpC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061270100612701006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22562 DVDDWk..DVDVDDWNDDVDDWDTDW9DXDWNDHr@Hs=Hr@HrłTHr.Hs=DVDWDW9DWNAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDT.DXD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW6DW9. Normal weightA NNYYNEGDW*DW5DW8DWkDX NEG....YNNNNYNDV........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW5DWDWBB(BBCPB=8-9 months A1-2 months A 7-8 monthsA9-10 months A . ...C4591001C4591001 1006 10061271100612711006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22566 DVDDW.DWDVDVDDW DDVDDW D....Hr4HrnxHr4Hrnx..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW[ .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW[. Normal weightA NNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061272100612721006AYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22821 DVDdDW.DWDVDVDdDWDDVDdDWD....HrHsrHrHsr..DV...AYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)ANN Y NN . DW.BNT162b2 (30 (*ESC*){unicode 03BC}g) Dd.D...82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NYYYNEGDWDWDXN..NEGDV.DVDVYNNNNYYDV........DW/DWNY NNN Ynot eligible for the study at randomization Yhad important protocol deviation(s) as determined by the clinician for Immunogenicity (on or before 3 weeks post Dose 1) Population(s) NNNYNNN YNNNNY NNDWDWDWBpCPB0-1 month A0-1 month A0-1 month A9-10 months A . ...C4591001C4591001 1006 10061273100612731006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22823 DVD,DW.DWDVDVD,DWDLDVD,DWDDWDְDWDLHr'Hs<Hr'HrjHssѰHs<DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. D,D.DְDL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NYYYNEGDW,DWDWDWDXfNEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BlBqCPB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061274100612741006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22830 DVDPDW.DWDVDVDPDWDDVDPDWD....Hr?Hr1Hr?Hr1..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. DPD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Underweight ANNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB~BpCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061276100612761006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22831 DVDDW.DWDVDVDDWDDVDDWDDWDDWDHrKHs(HrKHrִHst8Hs(DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW,DWDWDWDXrNEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBpC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061277100612771006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23159 DVDDW.DWDVDVDDWD DVDDWDDWDDWD HrpHs8 HrpHrpHssHs8 DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD .82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW/DWDWDWDXcNEG....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BlBpC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061278100612781006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23162 DVDDW.DWDVDVDDW DDVDDW D....HrHrOHrHrO..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Underweight ANNYYNEGDW)DWDW.. ....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBB@C@B8-9 months A6-7 months Ap0-1 month A9-10 months A . ...C4591001C4591001 1006 10061279100612791006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23166 DVDTDW.DWDVDVDTDWDDVDTDW DtDWDHDWDHrTHsJHrTHrėHsrBHsJDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DTDt.DHD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YYYYNEGDW)DWDWDWDXcNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBpC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061280100612801006AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23168 DVDDW.DWDVDVDDWDDVDDWD....HrHr6DHrHr6D..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Obese A@YYYYNEGDW1DWDW..NEG....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBQBB7-8 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1006 10061282100612821006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23314 DVD\DW.DWDVDVD\DWDtDVD\DWDt....HrHr2tHrHr2t..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. D\Dt....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Underweight ANNYYNEGDW3DWDW..NEG....YNNNNYYDV........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB~BpC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061283100612831006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23315 DVDPDW.DWDVDVDPDWDŔDVDPDWDؐDWDxDWDŔHrHsHrHrpHsvxHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DPDؐ.DxDŔ.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW,DWDWDWDXfNEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BjBpC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061284100612841006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23318 DVDDW.DWDVDVDDWDLDVDDWD0DWD$DWDLHrHsLHrHrȅ0Hs|HsLDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD0.D$DL.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW,DWDWDWDXkPOS....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBeBmC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061285100612851006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23702 DVDDW..DVDVDDWDôDVDDWDpDWDpDWDôHrHs4HrHrpHspHs4DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW]BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDp.DpDô.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW7DWDWDWDXrNEG....YNNNNYNDV........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB\B]CB8-9 months A5-6 months A`3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1006 10061286100612861006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23704 DVDDW.DWDVDVDDWDDVDDWD....HrHrytHrHryt..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWV .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWV. Underweight ANNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061287100612871006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV23706 DVDDW.DWDVDVDDWDDVDDWD....HrHr̄xHrHr̄x..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW` .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDW`. Underweight ANNYYNEGDW/DWDW..NEGDW.DWDWYNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB{ABB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061288100612881006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23708 DVDDW.DWDVDVDDWDDVDDWD....HrHr̄<HrHr̄<..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Normal weightA NNYYNEGDW/DW?DW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW?DWDWBB-BBBB7-8 months A1-2 months A 0-1 month A8-9 months A . ...C4591001C4591001 1006 10061289100612891006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23941 DVDDW.DWDVDVDDWD|DVDDWD|....HrHHrHrHHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW` .. DD|....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW`. Normal weightA NYYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBiBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061290100612901006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23943 DVDDW.DWDVDVDDWDDVDDWD....HrHr8HrHr8..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW` .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW`. Normal weightA NYYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBiBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1006 10061291100612911006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23946 DVD@DW.DWDVDVD@DWDDVD@DWDDWDDWDHrHs~XHrHrtHs{ذHs~XDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. D@D.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW6DWDWDWDXjNEG....YNNNNYNDV........DW6.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBfBiBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061292100612921006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23948 DVD<DW.DWDVDVD<DWDDVD<DWDDWD|DWDHrHsAxHrHr`Hsn8|HsAxDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. D<D.D|D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW1DWDWDWDX^NEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBpBqBB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061293100612931006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV24050 DVDDW..DVDVDDWDDVDDWD....HrHr`HrHr`..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW[ .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW[. Overweight A0NNYNPOSDW1DWDW..POS....YNNNNYYDV........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBByBqBB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1006 10061294100612941006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24054 DVDDW.DWDVDVDDWDDVDDWDԔDWDDWDHrHsHrHrͲHsvgHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDԔ.DD.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW0DWDWDWDXdNEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BjBmBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1006 10061295100612951006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24056 DWDDW.DWDWDWDDWD4DWDDWDDWDDWD4Hrc HsAHrc HraHsn8HsADWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD4.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANYYYNEGDW1DWDWDWDX^NEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBpBqBB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1006 10061296100612961006AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24611 DWD8DW.DWDWDWD8DWDDWD8DWD....Hr8HrpHr8Hrp..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW\ .. D8D....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDW\. Underweight ANNYYNEGDW7DWDW..NEG....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBABB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061297100612971006AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24612 DWDtDW.DWDWDWDtDWDDWDtDWD....HrtHr4HrtHr4..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWLOST TO FOLLOW-UP . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW\ .. DtD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW\. Normal weightA NNNYPOSDW7DWDW..POS....YNNNNYNDW........DW7.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNNNY NNDWDWDWBBABB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1006 10061298100612981006AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24617 DWDDW..DWDWDDWDDWDDWDDWD@DWDHr9HsHr9Hr HstHsDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D@D.82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YYYYNEGDW8DWDWDWDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBrBkBpBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1006 10061299100612991006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24618 DWDLDW.DWDWDWDLDWDDWDLDWD....HrLHrHrLHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWZ .. DLD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWZ. Underweight ANNYYNEGDW?DWDW..NEG....YNNNNYYDW........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBsBmBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1006 10061300100613001006AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW26122 DWDDW.DWDWDWDDW$DDWDDW$D....Hr1Hr޼Hr1Hr޼..DWDW$..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DD....82785 Peterson, James Todd ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Underweight ANNYYNEGDWADWDW..NEG....YNNNNYYDW........DWADWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBjBpBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071409100714091007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20265 DVD|DW.DWDVDVD|DWDDVD|DWD....Hrad|HsnHrad|Hsn..DV...AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)ANNYY NN . DW.BNT162b2 (30 (*ESC*){unicode 03BC}g) D|.D...13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANYYYNEGDWDWDXX..NEG....YNNNNYYDV........DVDWYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDWDWDWBmCB0-1 month A0-1 month A0-1 month A11-12 monthsA . ..DVC4591001C4591001 1007 10071414100714141007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20268 DVDDW.DWDVDVDDWDDVDDVDDWDDWDHraoHsaHHraoHr}+0Hsu|HsaHDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDVDWDWDWDXjNEG....YNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCpBBkBrCB10-11 monthsA6-7 months Ap3-4 monthsA@11-12 monthsA . ...C4591001C4591001 1007 10071415100714151007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20271 DVDDW.DWDVDVDDVDDVDDVD....HrayHrHrayHr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANN NYhad important protocol deviation(s) as determined by the clinician for Efficacy (prior to the first post(*ESC*){unicode 2013}Dose 2 N-binding antibody test) PopulationNY YDWG .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWG. Underweight ANNYYNEGDWDWDW..NEGDV5.DV5DV5YNNNNYYDV........DWDWYY NNNY Yhad important protocol deviation(s) as determined by the clinician for Efficacy (within 7 days post Dose 2), Immunogenicity (on or before 3 weeks post Dose 1) Population(s) Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1)Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NNNYYYN YNNYNY NYDWDWDWCBBrCB9-10 months A5-6 months A`0-1 month A11-12 monthsA . ...C4591001C4591001 1007 10071417100714171007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20272 DVDPDW.DWDVDVDPDVDDVDPDVD....HraPHr}#tHraPHr}#t..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DPD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW@.. Overweight A0NNYYNEGDVDW?DW..NEG....YNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW?DWDWCpBiBCB~10-11 monthsA3-4 months A@0-1 month A11-12 monthsA . ...C4591001C4591001 1007 10071428100714281007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20292 DVDDW.DWDVDVDDVDDVDDVD....HraHr}YHraHr}Y..DVDV..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Underweight ANNYYNEGDVDWDW..NEGDW.DWDWYNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCpBBqCB10-11 monthsA6-7 months Ap0-1 month A11-12 monthsA . ...C4591001C4591001 1007 10071429100714291007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20295 DVDDW.DWDVDVDDVD`DVDDVD`....HraHr}\HraHr}\..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD`....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDVDWDW..NEGDW.DWDWYNNNNYYDV........DVDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCpBBrCB10-11 monthsA6-7 months Ap0-1 month A11-12 monthsA . ...C4591001C4591001 1007 10071467100714671007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20296 DVDDW..DVDVDDVDdDVDDVDd....Hr8HridHr8Hrid..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDd....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWS.. Normal weightA NNYYNEGDWDWRDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWRDWDWCBUBCPBj9-10 months A3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1007 10071469100714691007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20298 DVDDW..DVDVDDVDDVDDVD....HrXHr|HrXHr|..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWCBBmCPB9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071471100714711007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20374 DVDDW.DWDVDVDDVD0DVDDVD0....HrHr0HrHr0..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWCBBqCPB9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071472100714721007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20375 DVD,DW.DWDVDVD,DWDhDVD,DVDDWDDWDhHrHs,hHrHrjHsr_`Hs,hDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. D,D.DDh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDXcNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBmBrCPB9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071475100714751007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20378 DVDhDW.DWDVDVDhDVDDVDhDVD....HrHrHrHr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DhD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWCBBlCPB9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071476100714761007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20446 DVDHDW.DWDVDVDHDVDDVDHDVD....Hr HrHr Hr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DHD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWCBBrCPB9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071478100714781007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20384 DVDDW.DWDVDVDDWDDVDDVDHDWDLDWDHrHsHrHrHHsv`LHsDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDH.DLD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDWDWDWDWDXeNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBjBrCPB9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071480100714801007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20447 DVDDW.DWDVDVDDWD$DVDDVDDWDxDWD$Hr!|HsIHr!|HrHsrlHsIDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DxD$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNYYNEGDWDWDWDWDXdNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBmBrCPB9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071481100714811007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20449 DVDDW..DVDVDDWDXDVDDVDDWDDWDXHrHsHrHr HsHsDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DDX.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDWDWDWDWDXxNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWDWBBBXBmC@B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071482100714821007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20455 DVDDW.DWDVDVDDVD DVDDVD ....Hr Hr Hr Hr ..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071483100714831007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20496 DVD`DW.DWDVDVD`DWvD$DVD`DVD4DWaDDWvD$Hr`HsN$Hr`Hr۴Hs3ILHsN$DVDVDWaDWvAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`D4.DD$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWa. Underweight ANNYYNEGDW"DWJDW`DWDX3NEG....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWJDWDWBBLBBC@Ba9-10 months A2-3 months A05-6 monthsA`9-10 months A . ...C4591001C4591001 1007 10071484100714841007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20497 DVDpDW.DWDVDVDpDWD DVDpDVDDWDDWD HrpHs HrpHrhHsulHs DVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD.DD .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW"DWDWDWDXeNEG....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBrC@B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071485100714851007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20503 DVDDW.DWDVDVDDVD,DVDDVD,....HrDHr,HrDHr,..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD,....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWCBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071488100714881007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20504 DVDDW.DWDVDVDDVDDVDDVD....Hr_Hr@Hr_Hr@..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071490100714901007AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20605 DVDDW.DWDVDVDDVDHDVDDVDH....HrlHrHrlHr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDH....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071492100714921007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20606 DVD8DW..DVDVD8DVD|DVD8DVD|....Hrs8Hr|Hrs8Hr|..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWL .. D8D|....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWL. Normal weightA NNYYNEGDWDWDW..NEGDW.DWDWYNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWCBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071494100714941007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20608 DVD|DW.DWDVDVD|DVD DVD|DVD ....HrqHr HrqHr ..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. D|D ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWCBBrC0B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071495100714951007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20610 DVDDW.DWDVDVDDWDtDVDDVD DWDݸDWDtHr|Hs<Hr|HrHs}8Hs<DVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD .DݸDt.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDXjNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBeBrC0B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071496100714961007AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20750 DVDDW.DWDVDVDDWDDVDDVDDWDDWDHr`HsQXHr`Hr0Hs{HsQXDVDVDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDWDWDWDWDXjNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBfBrC0B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071497100714971007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20746 DVD8DW.DWDVDVD8DVDHDVD8DVDH....HrĸHrHrĸHr..DVDV..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. D8DH....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Underweight ANNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC0B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071499100714991007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV20753 DVDDW.DWDVDVDDVD(DVDDVD(....HrHrHrHr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DD(....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWU. Underweight ANNYYNEGDWDWDW..NEGDW.DWDWYNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBrC B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071500100715001007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20756 DVDDW.DWDVDVDDVDDVDDVD....HrHr8HrHr8..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDWDW=DW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW=DWDWBB?BC BR9-10 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071504100715041007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21085 DVD,DW.DWDVDVD,DWDDVD,DWD....Hr,HrOTHr,HrOT..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D,D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Overweight A0NNYYNEGDW#DW=DW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWDWBB7BCBN8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071505100715051007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21087 DVD`DW.DWDVDVD`DWDˆDVD`DWDDWDDWDˆHr`Hs3Hr`Hr,Hs_<Hs3DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`D.DDˆ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NYYYNEGDW(DWDWDWDXs ....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBB]BpCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071506100715061007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21089 DVDxDW.DWDVDVDxDWD,DVDxDWD,....HrxHrHrxHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DxD,....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW}.. Normal weightA NNYYNEGDW!DW|DW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW|DWDWBBxBCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071507100715071007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21090 DVDdDW.DWDVDVDdDWD8DVDdDWDDWDDWD8HrdHsHrdHr`Hsu (HsDVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DdD.DD8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW!DWDWDWDXfNEG....YNNNNYNDV........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071508100715081007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21192 DVDDW.DWDVDVDDWDDVDDWD....Hr)HrHr)Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBlCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071509100715091007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21197 DVDθDW.DWDVDVDθDWDDVDθDWDDWDDWDHr6HsHr6HrOTHsv&HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DθD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW#DWDWDWDXeNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071511100715111007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21198 DVDDW.DWDVDVDDWDDVDDWDDWD DWDHrTHs7\HrTHrHss Hs7\DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW!DWDWDWDXdNEG....YNNNNYNDV........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBlBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071512100715121007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21276 DVDXDW.DWDVDVDXDWDDVDXDWD....HrZXHrHHrZXHrH..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DXD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW!DW=DW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWDWBB9BCBN8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071514100715141007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21199 DVDDW.DWDVDVDDWDDVDDWD....HrYHrHrYHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071515100715151007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV21283 DVDHDW.DWDVDVDHDWDDVDHDWD....HrCHrHrCHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DHD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDW"DWDW..NEGDW.DWDWYNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071516100715161007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21282 DVDDW.DWDVDVDDWDLDVDDWDPDWDԔDWDLHrB$Hs?HrB$Hr PHssϔHs?DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDP.DԔDL.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNNYPOSDW"DWDWDWDXdPOS....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBlBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071517100715171007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21284 DVD,DW.DWDVDVD,DWDDVD,DWD....HrPHrHHrPHrH..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D,D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071518100715181007AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21369 DVD`DW.DWDVDVD`DWDxDVD`DWDx....HrXHrxHrXHrx..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D`Dx....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Obese A@YNYYNEGDW"DW=DW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW=DWDWBB8BCBM8-9 months A2-3 months A00-1 month A9-10 months A . ...C4591001C4591001 1007 10071519100715191007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21374 DVDHDW.DWDVDVDHDWwDtDVDHDWDDWbDHDWwDtHraHsP)HraHr Hs4LHHsP)DVDWDWbDWwAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DHD.DHDt.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWaDWb. Normal weightA NNYYNEGDW#DW`DWaDWDX4NEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW`DWDWBB[BBCBp8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1007 10071520100715201007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21375 DVDtDW.DWDVDVDtDWD(DVDtDWD|DWD@DWD(HrbHs(HrbHr |Hs@Hs(DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DtD|.D@D(.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDX{NEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBVBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071521100715211007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21376 DVDˆDW.DWDVDVDˆDWDLDVDˆDWDL....Hr|Hr:LHr|Hr:L..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DˆDL....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBlCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071522100715221007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21458 DVDDW.DWDVDVDDWDDVDDWD|DWD0DWDHrXHs `HrXHr7|Hs~)0Hs `DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD|.D0D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW$DWDWDWDXlNEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBdBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071523100715231007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21453 DVDDW.DWDVDVDDWDDVDDWD....HrxHr HrxHr ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBlCB8-9 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1007 10071524100715241007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21462 DVDDWv..DVDVDDWUDDVDDWDDW@DLDWUDHrdHs#rHrdHr HsLHs#rDVDWDW@DWUAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DLD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW1DW@. Normal weightA NNYYNEGDW*DW0DW?DWvDXNEG....YNNNNYNDV........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW0DWDWBB+BBCB@8-9 months A1-2 months A 6-7 monthsAp9-10 months A . ...C4591001C4591001 1007 10071525100715251007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21463 DVD@DW.DWDVDVD@DWD@DVD@DWD@....HrHr @HrHr @..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D@D@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071526100715261007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21515 DVDHDW.DWDVDVDHDWDhDVDHDWDh....HrHr-hHrHr-h..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DHDh....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071527100715271007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21514 DVD,DW.DWDVDVD,DWDǰDVD,DWDXDWDDWDǰHrHs0HrHr.XHsHs0DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D,DX.DDǰ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANYYYNEGDW"DWDWDWDXrPOS....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBB\BqCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071528100715281007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV21521 DVDDW.DWDVDVDDWD@DVDDWD@....HrHryHrHry..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDW#DWDW..NEGDW.DWDWYNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071529100715291007AYEARSFA MULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21524 DVD0DW.DWDVDVD0DWDDVD0DWD....Hr0HrLHHr0HrLH..DVDW..AYEARS. 12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. D0D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071530100715301007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21589 DVDDW.DWDVDVDDWDDVDDWD....HrHrPHrHrP..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0YNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071531100715311007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21590 DVDhDW.DWDVDVDhDWD\DVDhDWDDWDdDWD\HrhHsHrhHrSHs|HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DhD.DdD\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW#DWDWDWDXrNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBeBqCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071533100715331007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21591 DVDxDW.DWDVDVDxDWDdDVDxDWDDWDDWDdHrxHsHrxHrbPHs~$HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DxD.DDd.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNNNPOSDW#DWDWDWDXlPOS....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBdBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071535100715351007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21596 DVD DW.DWDVDVD DWD<DVD DWD<....Hr HrnHr Hrn..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D D<....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNNNPOSDW#DW=DW..POS....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDW=DWDWBB7BCBL8-9 months A1-2 months A 0-1 month A9-10 months A . ..DWC4591001C4591001 1007 10071536100715361007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21681 DVDDW.DWDVDVDDWDߘDVDDWDߘ....HrHrHHrHrH..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWL .. DDߘ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWL. Underweight ANNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWxC4591001C4591001 1007 10071537100715371007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21683 DVDǰDW.DWDVDVDǰDWDDVDǰDWD....HrҰHr\HrҰHr\..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DǰD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Overweight A0NNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071539100715391007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21689 DVDTDW.DWDVDVDTDWDˬDVDTDWDʀDWD4DWDˬHrTHs<HrTHrHsHs<DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DTDʀ.D4Dˬ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW#DWDWDWDXsNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB]BrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071540100715401007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21685 DVDDW.DWDVDVDDWD(DVDDWDpDWD$DWD(HrHs9(HrHrHsHs9(DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDp.D$D(.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDXsNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB]BrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071541100715411007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21767 DVDDW.DWDVDVDDWED8DVDDWDhDW0DۜDWED8HrHsMHrHrHrHsMDVDWDW0DWEAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDh.DۜD8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW/DW0. Normal weightA NNYYNEGDW$DW.DW/DWaDWNEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDW.DWDWBB(BBCB=8-9 months A1-2 months A 7-8 monthsA9-10 months A . ...C4591001C4591001 1007 10071542100715421007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21769 DVDDW.DWDVDVDDWDDVDDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Normal weightA NNYYNEGDW(DWDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071543100715431007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV21771 DVD<DW.DWDVDVD<DWDHDVD<DWDH....Hr<HrHr<Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D<DH....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NYYYNEGDW#DWDW..NEGDW.DWDWYNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071544100715441007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21773 DVD,DW.DWDVDVD,DWDDVD,DWD....Hr,HrlHr,Hrl..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D,D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071546100715461007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21827 DVD8DW.DWDVDVD8DWDDVD8DWD....HrHrPHrHrP..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D8D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW#DW=DW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWDWBB7BCBK8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071547100715471007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21830 DVDtDW.DWDVDVDtDWDDVDtDWDDWDĤDWDHrHs HrHrX<HsvbHs DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DtD.DĤD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDXfNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBqCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071550100715501007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21832 DVDנDW..DVDVDנDWDDVDנDWD....Hr4 Hr|Hr4 Hr|..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DנD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANYYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071551100715511007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21835 DVDDW.DWDVDVDDWD\DVDDWDDWDDWD\Hr1PHscHr1PHr/Hs{HscDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW$DWDWDWDXjNEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBfBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071552100715521007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21976 DVD`DW.DWDVDVD`DWDшDVD`DWDƄDWDlDWDшHrFHsHrFHr/Hs~VlHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`DƄ.DlDш.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDXlNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBdBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071554100715541007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV21977 DVDDW.DWDVDVDDWDټDVDDWDټ....HrJdHr<HrJdHr<..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDټ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNNYPOSDW$DWDW..POSDW.DWDWYNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071555100715551007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21979 DVDpDW..DVDVDpDWD0DVDpDWD0....HrEHrG0HrEHrG0..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWK .. DpD0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWK. Underweight ANNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071557100715571007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21980 DVDhDW..DVDVDhDW DDVDhDW D....Hr*HrHr*Hr..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DhD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Normal weightA NNNYPOSDW+DWDW..POS....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071558100715581007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22284 DVDDW.DWDVDVDDW DLDVDDW DL....Hr-|HrLHr-|HrL..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDL....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBlCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071559100715591007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22285 DVDDW.DWDVDVDDWDDVDDW D܌DWD0DWDHrI`Hs-HrI`Hr.HsHs-DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD܌.D0D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW/DWDWDWDXmPOS....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBcBqCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1007 10071560100715601007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22286 DVDDW.DWDVDVDDWDDVDDW DHDWD<DWDHrlLHs+HrlLHr-Hsr]Hs+DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDH.D<D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW)DWDWDWDXcNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWDWBBBmBqCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071561100715611007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22288 DVDDW.DWDVDVDDW DDVDDW D....HrwPHr%HrwPHr%..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW)DWDW..NEG....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071562100715621007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22385 DVDDW.DWDVDVDDWDDVDDW D<DWDDWDHrHsHrHrB<HsrIHsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD<.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNNYPOSDW(DWDWDWDXcPOS....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNNDWDWDWBBBmBrCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071563100715631007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22386 DVDDW.DWDVDVDDWDDVDDW DDWDDWDHrlHs HrlHr@HsrJHs DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWKBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNNYPOSDW(DWDWDWDXcPOS....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBBmBrCpB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071564100715641007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22387 DVDhDW.DWDVDVDhDWDDVDhDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DhD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNNYPOSDW/DWDW..POS....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWDWBB~BrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071565100715651007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22388 DVD8DW.DWDVDVD8DWD@DVD8DWD@....HrHr@HrHr@..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D8D@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW/DWDW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB~BrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071566100715661007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22402 DVDXDW.DWDVDVDXDW D4DVDXDW D4....HrHr;4HrHr;4..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWL .. DXD4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWL. Normal weightA NNYYNEGDW(DWDW.. ....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBBlCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071567100715671007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22407 DVDDW.DWDVDVDDW DDVDDW D....HrHr%XHrHr%X..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW)DWDW..NEG....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071568100715681007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22409 DVD`DW.DWDVDVD`DWD\DVD`DW DDWDDWD\Hr`HsHr`HrĆ`HsHsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`D.DD\.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW)DWDWDWDXrNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB^BkC`B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071569100715691007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22411 DVDDW.DWDVDVDDWDDVDDW D<DWDXDWDHrHsHrHrfHsXHsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD<.DXD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW*DWDWDWDXsNEG....YNNNNYNDV........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBB\BrC`B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071570100715701007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22521 DVDPDW.DWDVDVDPDWD0DVDPDW DLDWDDWD0HrPHs0HrPHreHsHs0DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DPDL.DD0.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNN POSDW*DWDWDWDXsPOS....YNNNNYNDV........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBB\BrC`B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071571100715711007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22528 DVDDW.DWDVDVDDWDDVDDWD....HrHr݀HrHr݀..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB~BrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071572100715721007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22529 DVD<DW.DWDVDVD<DW DDVD<DW D....Hr<Hrą4Hr<Hrą4..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D<D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW)DWDW..NEG....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071573100715731007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV22532 DVDXDW.DWDVDVDXDW DDVDXDW D....HrXHr'HrXHr'..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DXD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDW*DWDW..NEGDW.DWDWYNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071574100715741007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22727 DVDDW.DWDVDVDDWDDVDDWD....Hr HrŲHr HrŲ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>DWT. Normal weightA NNYYNEGDW+DW=DW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWDWBB0BCPBE8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071575100715751007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22728 DVDՄDW.DWDVDVDՄDWDDVDՄDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DՄD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW>.. Normal weightA NNYYNEGDW*DW=DW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDW=DWDWBB0BCPBE8-9 months A1-2 months A 0-1 month A9-10 months A . ...C4591001C4591001 1007 10071576100715761007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22733 DVD4DW.DWDVDVD4DWDDVD4DWDިDWDDWDHrHsHrHrӨHslHsDVDWDWDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D4Dި.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DW}DW. Normal weightA NNYYNEGDW*DW|DWDWDX_NEG....YNNNNYNDV........DW*.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDW|DWDWBBoBrBCPB8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1007 10071577100715771007AYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22918 DVDDW.DWDVDVDDWDDVDDWDDWuDDWDHr<HsjO<Hr<HrHsMPHsjO<DVDWDWuDWAYEARSBYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWpDWu. Normal weightA NYYYNEGDW+DWoDWtDWDXHNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWoDWDWBBbBBCPBw8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1007 10071578100715781007AYEARSMAMULTIPLE A`NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22736 DVD(DW.DWDVDVD(DWDDVD(DWDLDWDDWDHr:HsWpHr:HrLHs{HsWpDVDWDWDWAYEARSAYEARS12-15 YearsAMULTIRACIAL A`ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. D(DL.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW+DWDWDWDXjNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BfBrCPB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071579100715791007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22920 DVDDW.DWDVDVDDWDDVDDWD....Hr=HrHr=Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWS .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWS. Underweight ANNYYNEGDW/DWDW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB~BrCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071580100715801007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22921 DVD`DW.DWDVDVD`DWDDVD`DWD....Hr>HrHr>Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D`D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB~BrCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071581100715811007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22928 DVDlDW.DWDVDVDlDWDDVDlDWDlDWDdDWDHrulHs3HrulHr$Hs{dHs3DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DlDl.DdD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW+DWDWDWDXjNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BfBrC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071582100715821007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23087 DVDDW.DWDVDVDDWDDVDDWD....HrwHr#HrwHr#..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB}BrC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071583100715831007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23146 DVDDW.DWDVDVDDWDxDVDDWDLDWD(DWDxHrHsxHrHr&Hss(HsxDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDL.D(Dx.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW+DWDWDWDXeNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BlBrC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071584100715841007AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23091 DVDDW.DWDVDVDDWDDVDDWD....Hr}Hr*PHr}Hr*P..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBpC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071585100715851007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23094 DVDTDW.DWDVDVDTDWDDVDTDWDDWDDWDHr~THslHr~THr'Hsr@HslDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DTD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNYYNEGDW+DWDWDWDXdNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BmBrC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071586100715861007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23096 DVDDW.DWDVDVDDWD DVDDWD0DWDDWD HrHsHrHr$HsHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD0.DD .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW+DWDWDWDXrNEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}B^BrC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1007 10071587100715871007AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23148 DVDDW.DWDVDVDDWDDVDDWD....HrHr+@HrHr+@..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB}BrC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1007 10071588100715881007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW23151 DWDDW.DWDWDWDDWD@DWDDWD@....HrHr@HrHr@..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. DD@....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Normal weightA NNYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071589100715891007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW23155 DWDDW.DWDWDWDDWDǰDWDDWDHDWDDWDǰHr HsðHr Hr֢HssHsðDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDH.DDǰ.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW8DWDWDWDXeNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBlBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071590100715901007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24372 DWDDW.DWDWDWDDWDlDWDDWDl....Hr,HrHlHr,HrHl..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. DDl....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Normal weightA NNYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071591100715911007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24378 DWDDW.DWDWDWDDWDDWDDWDDWDDWDHr`HsHr`Hr֛HHsb HsDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW>DWDWDWDXsPOS....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBrB]BqBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1007 10071592100715921007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24377 DWDxDW.DWDWDWDxDWD\DWDxDWD\....HrHr֝HrHr֝..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW? .. DxD\....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Underweight ANNYYNEGDW?DWDW..NEG....YNNNNYYDW........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071593100715931007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24380 DWDDW3.DW3DWDWDDWDDWDDWD....Hr͜Hr͜Hr͜Hr͜..DW...AYEARS. 12-15 YearsAWHITE AWHITE ADW3PROTOCOL DEVIATION DWPROTOCOL DEVIATION BNT162b2 Phase 2/3 (30 mcg)ANNYY NN . .. D.....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo DW3.. Normal weightA NYYYNEGDW2DW2DW.. DW.DWDWYNNNNNNDW..........YY NNN Yhad important protocol deviation(s) as determined by the clinician for Immunogenicity (on or before 1 month post Dose 2) Population(s) Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNYNY NNDW2DW3DW3AB/B.0-1 month A0-1 month A0-1 month A1-2 months A . ...C4591001C4591001 1007 10071594100715941007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24453 DWDDW.DWDWDWDDWDDWDDWD....HrLHrdHrLHrd..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW=. Underweight ANNYYNEGDW=DWDW..NEG....YNNNNYYDW........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071595100715951007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24454 DWDИDW.DWDWDWDИDWDDWDИDWDDWD$DWDHrHs|HrHrֱPHss$Hs|DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DИD.D$D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW8DWDWDWDXfNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBlBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071596100715961007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24456 DWDDW.DWDWDWDDWDDWDDWDpDWDDWDHrHs5tHrHrDpHs{Hs5tDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDp.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW8DWDWDWDXjNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBpBfBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071597100715971007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24460 DWD$DW.DWDWDWD$DWDXDWD$DWDX....HrHrHrHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. D$DX....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Underweight ANNYYNEGDW>DWDW..NEG....YNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBrBqBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071599100715991007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24478 DWD`DW.DWDWDWD`DWD(DWD`DWD(....HrHr¨HrHr¨..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. D`D(....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Underweight ANNYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071600100716001007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24479 DWDPDW..DWDWDPDWDDWDPDWD8DWDlDWDHrHs(HrHrHslHs(DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DPD8.DlD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW8DWDWDWDXNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqB^BrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071601100716011007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24481 DWDDW.DWDWDWDDWD4DWDDWD4....Hr(HrHr(Hr..DWDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWS .. DD4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWS. Normal weightA NNYYNEGDWSDWDW..NEGDW.DWDWYNNNNYYDW........DWSDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071602100716021007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24483 DWDDW.DWDWDWDDWD DWDDWD ....HrHrHrHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. DD ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Underweight ANNYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071603100716031007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24539 DWDDW.DWDWDWDDWDDWDDWD....HrHr HrHr ..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NYYYNEGDW>DWDW..NEGDW.DWDWYNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBrBqBB8-9 months A4-5 months AP0-1 month A8-9 months A . ..DW>C4591001C4591001 1007 10071604100716041007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24538 DWDDW.DWDWDWDDWDDWDDWD....HrHr,HrHr,..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDW8. Overweight A0NNYYNEGDW8DWDW..NEGDW.DWDWYNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071605100716051007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24544 DWD\DW.DWDWDWD\DWDDWD\DWD....Hr\Hr֥\Hr\Hr֥\..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. D\D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Underweight ANNYYNEGDW>DWDW..NEG....YNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071606100716061007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24545 DWDDDW.DWDWDWDDDWDpDWDDDWDp....HrDHrHrDHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWG .. DDDp....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWG. Normal weightA NNYYNEGDWGDWDW..NEG....YNNNNYYDW........DWGDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBrBqBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071607100716071007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24683 DWD4DW.DWDWDWD4DWD8DWD4DWDDWDDWD8Hr44HsHr44Hr HssHsDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D4D.DD8.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW?DWDWDWDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBlBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071608100716081007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24684 DWDDW..DWDWDDWD DWDDWDTDWDDWD Hr2HsHr2HrHssHsDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDT.DD .13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW?DWDWDWDXfNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBlBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071609100716091007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24685 DWD\DW..DWDWD\DWDDWD\DWD....Hr9\HrHHr9\HrH..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. D\D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW=. Normal weightA NNYYNEGDW=DWDW..NEG....YNNNNYYDW........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071610100716101007AYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24730 DWDDW.DWDWDWDDWDDWDDWD....Hr=HrٜHr=Hrٜ..DWDW..AYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW9 .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW}DW9. Obese A@YNYYNEGDW9DW|DW..NEG....YNNNNYYDW........DW9DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDW|DWDWBB`BBBw8-9 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071612100716121007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24692 DWDDW.DWDWDWDDWDDWDDWD....Hr;HrPHr;HrP..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW@ .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW@. Normal weightA NNYYNEGDW@DWDW..NEG....YNNNNYYDW........DW@DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071613100716131007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24732 DWD DW.DWDWDWD DWDDWD DWDϨDWDDWDHrM HslHrM Hr(Hs|4HslDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. D DϨ.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW8DWDWDWDXkNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBeBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ..DWRC4591001C4591001 1007 10071614100716141007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24734 DWD`DW.DWDWDWD`DWDDWD`DWDDWD,DWDHrS`Hs|HrS`HrHsvq,Hs|DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. D`D.D,D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW>DWDWDWDXxNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBjBrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071615100716151007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24740 DWDDW.DWDWDWDDWDDWDDWD....HrLHrxHrLHrx..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Normal weightA NNYYNEGDW>DWDW..NEG....YNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071616100716161007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24777 DWDDDW.DWDWDWDDDWDôDWDDDWDô....HrQDHr4HrQDHr4..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DDDô....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Normal weightA NNYYNEGDW>DWDW..NEG....YNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBrBqBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071617100716171007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24781 DWDXDW.DWDWDWDXDWDDWDXDWDhDWuDhDWDHr[XHsi^Hr[XHrLhHsMGHsi^DWDWDWuDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW8BNT162b2 (30 (*ESC*){unicode 03BC}g).. DXDh.DhD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWjDW8. Normal weightA NNYYNEGDW8DWiDWtDWDXGNEG....YNNNNYNDW........DW8.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWiDWDWBBNBBBBd8-9 months A2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1007 10071618100716181007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24784 DWDDW.DWDWDWDDWD0DWDDWD0....Hr[Hr֜Hr[Hr֜..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD0....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDW?DWDW..NEGDW.DWDWYNNNNYYDW........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBqBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071619100716191007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24785 DWDDW.DWDWDWDDWDDWDDWD....HrCHrHrCHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW? .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Underweight ANNYYNEGDW?DWDW..NEG....YNNNNYYDW........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071620100716201007AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24828 DWDDW.DWDWDWDDWDDWDDWD....HrM8HrRHrM8HrR..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW9DWDW..NEG....YNNNNYYDW........DW9DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBBuBmBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071621100716211007AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW24830 DWD,DW.DWDWDWD,DWDDWD,DWD....HrQHrRHrQHrR..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D,D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Underweight ANNYNPOSDW9DWDW..NEG....YNNNNYYDW........DW9DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBuBmBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071622100716221007AYEARSMAWHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24831 DWDDW.DWDWDWDDWDDWDDWD....HrPDHrPDHrPDHrPD..DW...AYEARS. 12-15 YearsAWHITE AWHITE A. DWOTHER BNT162b2 Phase 2/3 (30 mcg)ANNYY NN . .. D.....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW6.. Normal weightA NNYYNEGDW5DW5DW.. ....YNNNNYYDW........DW9DWYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDW5DWDWBBB/0-1 month A0-1 month A0-1 month A8-9 months A . ..DW C4591001C4591001 1007 10071623100716231007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24832 DWDtDW.DWDWDWDtDWDDWDtDWDTDWDDWDHrTHslHrTHr٢HsLHslDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DtDT.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANYYYNEGDW?DWDWDWDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBoB^BrBB8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071624100716241007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24910 DWDDW.DWDWDWDDWD4DWDDW"DdDWDDWD4Hre Hs$4Hre HrdHsuXHs$4DWDW"DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDd.DD4.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW>DWDWDWDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBkBkBqBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ..DWC4591001C4591001 1007 10071625100716251007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24915 DWDDW.DWDWDWDDWDDWDDW"DtDWD$DWDHrg<Hs"Hrg<HrtHsuHs"DWDW"DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDt.D$D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW>DWDWDWDXcNEG....YNNNNYNDW........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBkBkBqBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ..DWwC4591001C4591001 1007 10071626100716261007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24917 DWD DW.DWDWDWD DWDDWD DWD....HrHrHrHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. D D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Underweight ANNYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071627100716271007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24919 DWD̜DW.DWDWDWD̜DWD~DWD̜DWD~....HrHrHrHr..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW8 .. D̜D~....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW8. Normal weightA NYYYNEGDW8DWDW..NEG....YNNNNYYDW........DW8DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071628100716281007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24997 DWDXDW.DWDWDWDXDWDƄDWDXDWDƄ....HrHr0HrHr0..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. DXDƄ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW=. Underweight ANNYYNEGDW=DWDW..NEG....YNNNNYYDW........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBrBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071629100716291007AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24994 DWD|DW.DWDWDWD|DWDDWD|DWD@DWD̜DWDHrHsτHrHr@Hs<HsτDWDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D|D@.D̜D.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NYYYNEGDW?DWDWDWDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBpB^BrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071630100716301007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24993 DWDDW.DWDWDWDDWDDWDDWDDWDDWDHrHs(HrHrHs>Hs(DWDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW?DWDWDWDXrNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBpB^BrBB8-9 months A4-5 months AP3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071631100716311007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25003 DWDDW.DWDWDWDDWDDWDDWD....HrHrٝpHrHrٝp..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW@DWDW..NEG....YNNNNYYDW........DW@DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBpBqBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071632100716321007AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25062 DWDDW.DWDWDWDDWDDWDDWDlDWDPDWDHr Hs9Hr Hr]HssPHs9DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDl.DPD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW?DWDWDWDXdNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBoBlBrBB8-9 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071633100716331007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25058 DWDDW.DWDWDWDDWDDWDDWD....HrHr٠|HrHr٠|..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Normal weightA NNYYNEGDW>DWDW..NEG....YNNNNYYDW........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBqBpBB8-9 months A4-5 months AP0-1 month A8-9 months A . ...C4591001C4591001 1007 10071634100716341007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25064 DW DDW.DWDW DW DDW!DDW DDW!D....HrHrޜlHrHrޜl..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW=DWDW..NEG....YNNNNYYDW ........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071635100716351007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25063 DW DDW.DWDW DW DDW!DDW DDW!D....HrHrPHrHrP..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY SUBJECT . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDW=. Normal weightA NYYYNEGDW=DWDW..NEGDW.DWDWYNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBlBkABB3-4 months A@3-4 months A@0-1 month A4-5 months AP . ...C4591001C4591001 1007 10071636100716361007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25149 DW DDW.DWDW DW DDW!DDW DDW!D....HrHrގ HrHrގ ..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW=. Overweight A0YNYYNEGDW=DWDW..NEG....YNNNNYYDW ........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071638100716381007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25153 DW D<DW.DWDW DW D<DW!DDW D<DW!D....Hr<HrއHr<Hrއ..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW? .. D<D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Normal weightA NNYYNEGDW?DWDW..NEG....YNNNNYYDW ........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071639100716391007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25154 DW DDW.DWDW DW DDW!D4DW DDW!D4....HrHrށHrHrށ..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWD .. DD4....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWD. Normal weightA NNYYNEGDWDDWDW..NEG....YNNNNYNDW ........DWD.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBlBBB4-5 months AP3-4 months A@0-1 month A5-6 months A` . ...C4591001C4591001 1007 10071640100716401007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25156 DW DDW.DWDW DW DDWDhDW DDW!DDWDDWDhHrHsHrHr@HsHsDW DW!DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DDh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWEDWDWDWDXrNEG....YNNNNYNDW ........DWE.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBlB\BqBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071641100716411007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25202 DW D(DW.DWDW DW D(DW"DDW D(DW"D....Hr(Hr-Hr(Hr-..DW DW"..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW? .. D(D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Normal weightA NNYYNEGDW?DWDW..NEG....YNNNNYYDW ........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBqBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071642100716421007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25205 DW D,DW.DWDW DW D,DWDθDW D,DWDθ....Hr%,Hs8Hr%,Hs8..DW ...AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANNYY NN . DW.BNT162b2 (30 (*ESC*){unicode 03BC}g) D,.Dθ...13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDWDWDXX.. ....YNNNNYYDW ........DW=DWYY YNN Ydid not receive all vaccination(s) as randomized or did not receive Dose 2 within the predefined window (19-42 days after Dose 1) did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NNNYNNN YNNNNY NNDWDWDWBqBB0-1 month A0-1 month A0-1 month A8-9 months A . ..DWC4591001C4591001 1007 10071643100716431007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25204 DW DDW.DWDW DW DDWDDW DDW!DDWDИDWDHr#Hs`Hr#HrlHsHs`DW DW!DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DИD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW=DWDWDWDXt ....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBkBcBrBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071644100716441007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25294 DW DpDW..DW DW DpDW!DDW DpDW!D....Hr;pHrhHr;pHrh..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW= .. DpD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW=. Underweight ANNYYNEGDW=DWDW..NEG....YNNNNYYDW ........DW=DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071645100716451007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25208 DW D(DW.DWDW DW D(DWDDW D(DW!DDWDDWDHr8(HsȄHr8(Hr4Hs~.HsȄDW DW!DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D(D.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW=DWDWDWDXlNEG....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBkBdBrBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071646100716461007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25299 DW D,DW.DWDW DW D,DWDTDW D,DW!DLDWDPDWDTHrC,HsHrC,HrHsPHsDW DW!DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW=BNT162b2 (30 (*ESC*){unicode 03BC}g).. D,DL.DPDT.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW=DWDWDWDXrNEG....YNNNNYNDW ........DW=.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBlB\BqBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071647100716471007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25302 DW DDW.DWDW DW DDW!DDW DDW!D....HrEHrlHrEHrl..DW DW!..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW@ .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW@. Normal weightA NYYYNEGDW@DWDW..NEG....YNNNNYYDW ........DW@DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBmBpBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071648100716481007AYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25304 DW DDW.DWDW DW DDWDDW DDW"DDWvDDWDHr(dHsji@Hr(dHrHsN¨Hsji@DW DW"DWvDWAYEARSBYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWuDWv. Normal weightA NNYYNEGDW>DWtDWuDWDXHNEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWtDWDWBBSBBBBh7-8 months A2-3 months A04-5 monthsAP8-9 months A . ...C4591001C4591001 1007 10071649100716491007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25369 DW DtDW.DWDW DW DtDW"DDW DtDW"D....Hr.Hr)Hr.Hr)..DW DW"..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DtD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Normal weightA NNYYNEGDW>DWDW..NEG....YNNNNYYDW ........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBqBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071650100716501007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25370 DW DDW..DW DW DDWDDW DDW"DDWDpDWDHr@LHsHr@LHrHs}HsDW DW"DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DpD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNYYNEGDW@DWDWDWDXkNEG....YNNNNYNDW ........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBjBeBrBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071651100716511007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25373 DW DDW.DWDW DW DDW"DDW DDW"D....Hr=HrHr=Hr..DW DW"..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Underweight ANNYYNEGDW>DWDW..NEG....YNNNNYYDW ........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBjBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071652100716521007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW 25376 DW DDW.DWDW DW DDWDDW DDW"D\DWDDWDHrB,HslHrB,Hr\Hs|HHslDW DW"DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW>BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD\.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW>DWDWDWDXqNEG....YNNNNYNDW ........DW>.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBjBeBrBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071653100716531007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW 25437 DW DʼDW.DWDW DW DʼDW"DθDW DʼDW"Dθ....Hrn<Hr!Hrn<Hr!..DW DW"..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DʼDθ....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW>. Overweight A0YNYYNEGDW>DWDW..NEG....YNNNNYYDW ........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBkBqBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071654100716541007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW 25443 DW D(DW.DWDW DW D(DW"DDW D(DW"D....HrkHr"HrkHr"..DW DW"..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANNYY NN Y. .. D(D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Underweight ANNYYNEGDW>DWDW.. DW.DWDWYNNNNNNDW ..........YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 did not have N-binding test result at a post(*ESC*){unicode 2013}Dose 2 visit NYYYYYN YNNYNY NNDWDWDWBBjBrBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071655100716551007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25445 DWDDW.DWDWDWDDWDhDWDDW#DLDWDټDWDhHr{Hs;hHr{Hr*Hsr<Hs;hDWDW#DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDL.DټDh.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW?DWDWDWDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBiBmBrBB~7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071656100716561007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25448 DWDDW.DWDWDWDDW#DDWDDW#D....HrńHrvHrńHrv..DWDW#..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWE .. DD....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWE. Normal weightA NNYYNEGDWEDWDW..NEG....YNNNNYYDW........DWEDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBoBlBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071658100716581007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25838 DWDDW.DWDWDWDDWDDWDDW#DDWDDWDHrHs-HrHr9HsrlHs-DWDW#DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0NNYYNEGDW?DWDWDWDXcNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBiBmBrBB~7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ...C4591001C4591001 1007 10071659100716591007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25834 DWD\DW..DWDWD\DW#DDWD\DW#D....Hr\HrᄐHr\Hrᄐ..DWDW#..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW? .. D\D....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW?. Normal weightA NNYYNEGDW?DWDW..NEG....YNNNNYYDW........DW?DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBoBlBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071660100716601007AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW25833 DWDlDW..DWDWDlDWD$DWDlDW#D\DWDDWD$HrlHsHrlHrHsq HsDWDW#DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. DlD\.DD$.13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW?DWDWDWDXtNEG....YNNNNYNDW........DW?.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBoB]BlBB7-8 months A3-4 months A@3-4 monthsA@8-9 months A . ..DWrC4591001C4591001 1007 10071661100716611007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW25840 DWDDW.DWDWDWDDW$DhDWDDW$Dh....Hr xHrhHr xHrh..DWDW$..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW@ .. DDh....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW@. Normal weightA NNYYNEGDW@DWDW..NEG....YNNNNYYDW........DW@DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBnBlBB7-8 months A3-4 months A@0-1 month A8-9 months A . ...C4591001C4591001 1007 10071662100716621007AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DW26061 DWDDW.DWDWDWDDW$DLDWDDW$DL....Hr)$Hr|LHr)$Hr|L..DWDW$..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDL....13351 Frenck, Robert Wilson ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNNNPOSDW@DWDW..POSDW.DWDWYNNNNYYDW........DW@DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBiBqBB~7-8 months A3-4 months A@0-1 month A8-9 months A . ..DW$C4591001C4591001 1008 10081751100817511008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20520 DVDDW.DWDVDVDDWDDDVDDWD0DWDǰDWDDHrHsHrHr0Hsn|HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWZBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD0.DǰDD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW!DWDWDWDX`NEG....YNNNNYNDV........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBrC@B9-10 months A5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081752100817521008AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20525 DVDDW.DWDVDVDDWDˆDVDDVDDWDDWDˆHrXHs'HrXHrPHslHs'DVDVDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DDˆ.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDWDWDWDWDX`NEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBrC@B9-10 months A5-6 months A`4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081753100817531008AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20521 DVDDDW.DWDVDVDDDVDDVDDDVD....HrXDHrHrXDHr..DVDV..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWS .. DDD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWS. Normal weightA NNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC@B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1008 10081754100817541008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20527 DVDˆDW.DWDVDVDˆDVD|8DVDˆDVD|8....HrHrHrHr..DVDV..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DˆD|8....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDWDWDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrC0B9-10 months A5-6 months A`0-1 month A9-10 months A . ...C4591001C4591001 1008 10081755100817551008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20702 DVD,DW.DWDVDVD,DWDDVD,DWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D,D....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWo.. Normal weightA NNYYNEGDWDWnDW..NEG....YNNNNYYDV........DWDWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWnDWDWBBoBC0B9-10 months A3-4 months A@0-1 month A9-10 months A . ...C4591001C4591001 1008 10081756100817561008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20704 DVDʼDW.DWDVDVDʼDWDDVDʼDVDְDWxD8DWDHr<HskHr<Hr0HsQ8HskDVDVDWxDWAYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DʼDְ.D8D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWwDWx. Underweight ANYYYNEGDWDWvDWwDWDXINEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWvDWDWBBxBBC0B9-10 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081757100817571008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV20705 DVDDW.DWDVDVDDWDDVDDVDDWDôDWDHrHsHrHr|Hsrm4HsDVDVDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWkBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DôD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDWDWDWDWDXcNEG....YNNNNYNDV........DW.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBrC0B9-10 months A5-6 months A`3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081758100817581008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV20707 DVDDW.DWDVDVDDWDDVDDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWOTHER . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWN .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWN. Overweight A0NNYYNEGDW!DWDW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBSBB7-8 months A5-6 months A`0-1 month A8-9 months A . ...C4591001C4591001 1008 10081760100817601008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21257 DVD\DW.DWDVDVD\DWDDDVD\DWDD....HrG\HrHrG\Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. D\DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Normal weightA NNYYNEGDW"DWDW..NEG....YNNNNYYDV........DW"DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081761100817611008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21256 DVDDW.DWDVDVDDW}DDVDDWDDWgDDW}DHr:HsXHr:HrtHs;"HsXDVDWDWgDW}AYEARSBYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWgDWg. Obese A@YNYYNEGDW%DWfDWfDWDX:POS....YNNNNYNDV........DW%.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWfDWDWBBbBBCBw8-9 months A3-4 months A@5-6 monthsA`9-10 months A . ...C4591001C4591001 1008 10081763100817631008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21260 DVDDW.DWDVDVDDWDDVDDWDDWDĤDWDHrOHsHrOHrr|Hsu$HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DĤD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Obese A@YNYYNEGDW!DWDWDWDXeNEG....YNNNNYNDV........DW!.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBkBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081764100817641008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21258 DVDdDW.DWDVDVDdDWDDVDdDWD....HrNdHr[HHrNdHr[H..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DdD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Overweight A0NNYYNEGDW!DWDW..NEG....YNNNNYYDV........DW!DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1008 10081767100817671008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21468 DVDDW.DWDVDVDDWDDVDDWDDWDDWDHrHsϬHrHrHsmO HsϬDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWaBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW"DWDWDWDX_NEG....YNNNNYNDV........DW".YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBrCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081768100817681008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV21469 DVDDW.DWDVDVDDWDDVDDWD....HrHr&HrHr&..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DWDWO. Normal weightA NNYYNEGDW%DWDW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081769100817691008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21475 DVDDW.DWDVDVDDWDDVDDWD....HrPHrHrPHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW> .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWvDW>. Underweight ANYYYNEGDW>DWuDW..NEG....YNNNNYYDV........DW>DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWuDWDWBBpBCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081770100817701008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21476 DVDDW.DWDVDVDDWDDVDDWD....HrHr]dHrHr]d..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWN .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWN. Normal weightA NNNYPOSDW#DWDW..POS....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNNDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ..DWC4591001C4591001 1008 10081771100817711008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21662 DVDXDW.DWDVDVDXDWDDVDXDWD....HrXHr^HrXHr^..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWN .. DXD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWN. Normal weightA NNYYNEGDW#DWDW..NEG....YNNNNYYDV........DW#DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081773100817731008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21664 DVD(DW..DVDVD(DWDDVD(DWDDWDDWDHr(HshHr(Hr Hsn`HshDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW?BNT162b2 (30 (*ESC*){unicode 03BC}g).. D(D.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDX`NEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBrCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081774100817741008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21668 DVDDW.DWDVDVDDWD(DVDDWD(....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWF .. DD(....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWF. Normal weightA NNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081775100817751008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21667 DVD<DW.DWDVDVD<DWDDVD<DWD8DWDȠDWDHr<HsHHr<HrHsw HsHDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWFBNT162b2 (30 (*ESC*){unicode 03BC}g).. D<D8.DȠD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW$DWDWDWDXnNEG....YNNNNYNDV........DW$.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBiBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081777100817771008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21873 DVDDW.DWDVDVDDWDDVDDWD....HrXHrHrXHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWU .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWU. Underweight ANNYYNEGDW$DWDW..NEG....YNNNNYYDV........DW$DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081780100817801008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21875 DVDDW.DWDVDVDDWDhDVDDWDDWDDWDhHr.DHshHr.DHrHsr4|HshDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DDh.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW#DWDWDWDXcNEG....YNNNNYNDV........DW#.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBmBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081781100817811008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV21878 DVDhDW.DWDVDVDhDWDDVDhDWD8DWDDWDHr/HsHr/Hr8Hsv/HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DhD8.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW)DWDWDWDXeNEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBjBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081785100817851008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV21880 DVD͌DW.DWDVDVD͌DWD\DVD͌DWD\....Hr{HrNHr{HrN..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWY .. D͌D\....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWY. Normal weightA NNYYNEGDW%DWDW..NEG....YNNNNYYDV........DW%DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081788100817881008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22317 DVDDW.DWDVDVDDWDLDVDDW D DWDTDWDLHr3HsLHr3Hr HslHsLDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD .DTDL.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW(DWDWDWDX_NEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBqCpB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081789100817891008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22321 DVDDW.DWDVDVDDW D8DVDDW D8....Hr4Hr 8Hr4Hr 8..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. DD8....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081790100817901008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22322 DVDDW.DWDVDVDDWDDVDDW DxDWD`DWDHrlHs͐HrlHrxHslHs͐DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDx.D`D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW)DWDWDWDX_NEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBrCpB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081791100817911008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22357 DVDՄDW.DWDVDVDՄDW DDVDՄDW D....HrxHrHrxHr..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWD .. DՄD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWD. Underweight ANNYYNEGDW(DWDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081792100817921008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22323 DVDtDW.DWDVDVDtDW DDVDtDW D....HrxHrHrxHr..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWD .. DtD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWD. Normal weightA NNYYNEGDW(DWDW..NEG....YNNNNYYDV........DW(DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrCpB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081793100817931008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22359 DVDDW.DWDVDVDDWDDVDDW DLDWDƄDWDHrz\HsHrz\HrLHsm*HsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DDL.DƄD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW(DWDWDWDX_NEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBrCpB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081794100817941008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22358 DVDDW.DWDVDVDDWDDVDDW DDWD͌DWDHr{HsHr{HrHsm1 HsDVDW DWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWABNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D͌D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW(DWDWDWDX_NEG....YNNNNYNDV........DW(.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBqBrCpB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081795100817951008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22363 DVDLDW.DWDVDVDLDWDDVDLDWD....HrLHrHrLHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DLD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB}BrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081796100817961008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22570 DVDƄDW.DWDVDVDƄDWDDVDƄDW DDWDDDWDHrHsHrHruHsnCDHsDVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DƄD.DDD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW)DWDWDWDX_NEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBrC`B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081797100817971008AYEARSFA AMERICAN INDIAN OR ALASKA NATIVE A0HISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22574 DVDDW.DWDVDVDDW D`DVDDW D`....HrHr~HrHr~..DVDW ..AYEARS. 12-15 YearsAAMERICAN INDIAN OR ALASKA NATIVE A0ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWG .. DD`....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWG. Overweight A0NNYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBBBrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081798100817981008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22575 DVDְDW.DWDVDVDְDWDXDVDְDW D4DWD4DWDXHrʰHs)HrʰHr}Hsnb4Hs)DVDW DWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DְD4.D4DX.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANYYYNEGDW)DWDWDWDX`NEG....YNNNNYNDV........DW).YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBBpBrC`B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081799100817991008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22577 DVDDW.DWDVDVDDW DDVDDW D....HrHr5HHrHr5H..DVDW ..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWK .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWK. Normal weightA NNYYNEGDW)DWDW..NEG....YNNNNYYDV........DW)DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBBrC`B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081800100818001008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22775 DVD`DW.DWDVDVD`DWDDDVD`DWDD....HrHrŰDHrHrŰD..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. D`DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANYYYNEGDW*DWDW..NEG....YNNNNYYDV........DW*DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB~BrCPB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081801100818011008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22776 DVD(DW.DWDVDVD(DWDlDVD(DWDDWDDWDlHr2(HslHr2(HrHsrn`HslDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. D(D.DDl.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NYYYNEGDW,DWDWDWDXcNEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB|BmBrC@B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081802100818021008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV22780 DVDDW.DWDVDVDDWDhDVDDWDh....Hr\HrHr\Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DDh....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Underweight ANNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB}BrC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081803100818031008AYEARSMABLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV22783 DVDDW.DWDVDVDDWkDxDVDDWDDWVDŔDWkDxHr^Hs@SHr^Hr4Hs$Hs@SDVDWDWVDWkAYEARSBYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DŔDx.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWKDWV. Obese A@YNYYNEGDW+DWJDWUDWDX(NEG....YNNNNYNDV........DW+.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWJDWDWBB<BBC@BQ8-9 months A2-3 months A06-7 monthsAp9-10 months A . ...C4591001C4591001 1008 10081804100818041008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23122 DVDθDW.DWDVDVDθDWDDVDθDWDؐDWD@DWDHreHsHreHrHsm1HsDVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWUBNT162b2 (30 (*ESC*){unicode 03BC}g).. DθDؐ.D@D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW2DWDWDWDX_NEG....YNNNNYNDV........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BqBrC@B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081805100818051008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23123 DVDڬDW.DWDVDVDڬDWDpDVDڬDWDp....HrqHr HrqHr ..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWZ .. DڬDp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWZ. Normal weightA NNYYNEGDW,DWDW..NEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB}BrC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081806100818061008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23127 DVD|DW..DVDVD|DWDDVD|DWD....Hrt|HrHrt|Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWZ .. D|D....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWZ. Normal weightA NNYYNEGDW+DWDW..NEG....YNNNNYYDV........DW+DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB}BrC@B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081807100818071008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23129 DVD|DW.DWDVDVD|DWDDVD|DWDDWDDWDHrzHs4HrzHr?HsnCHs4DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWRBNT162b2 (30 (*ESC*){unicode 03BC}g).. D|D.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Overweight A0YNYYNEGDW,DWDWDWDX`NEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB|BpBrC0B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081808100818081008AYEARSMAASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23301 DVDDW.DWDVDVDDWDDVDDWDDWDDWDHr~HsHr~Hr>Hsr3HsDVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW`BNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW3DWDWDWDXcNEG....YNNNNYNDV........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNYYNYDWDWDWBB|BmBrC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081809100818091008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23306 DVD DW.DWDVDVD DWDDVD DWD0DWD@DWDHrHsHrHrI0HsmOHsDVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDW[BNT162b2 (30 (*ESC*){unicode 03BC}g).. D D0.D@D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW0DWDWDWDX_NEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB|BqBrC0B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081810100818101008AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23307 DVDDW.DWDVDVDDWD$DVDDWD$....HrPHr7$HrPHr7$..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW` .. DD$....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW`. Normal weightA NNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081811100818111008AYEARSFA WHITE AHISPANIC OR LATINO A .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23308 DVD,DW.DWDVDVD,DWDpDVD,DWDp....HrHr6pHrHr6p..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW` .. D,Dp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW`. Overweight A0NNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081812100818121008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23385 DVDɐDW.DWDVDVDɐDWDDVDɐDWDDWDtDWDHrHs$HrHrfHsmHHs$DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWSBNT162b2 (30 (*ESC*){unicode 03BC}g).. DɐD.DtD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDWDX`NEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB|BqBrC0B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081813100818131008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23392 DVDθDW.DWDVDVDθDWD<DVDθDWD<....Hr8Hr=<Hr8Hr=<..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DθD<....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW/DWDW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081814100818141008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23394 DVDDW.DWDVDVDDWDDVDDWD....Hr@HrmHr@Hrm..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW. Normal weightA NNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081815100818151008AYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23396 DVDDW.DWDVDVDDWDDVDDWDИDWDDWDHrHsdHrHrhHsv]HsdDVDWDWDWAYEARSAYEARS12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDИ.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW,DWDWDWDXfNEG....YNNNNYNDV........DW,.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB}BjBqC0B8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081816100818161008AYEARSFA BLACK OR AFRICAN AMERICAN A NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23412 DVDdDW.DWDVDVDdDWDDVDdDWD....HrHriHrHri..DVDW..AYEARS. 12-15 YearsABLACK OR AFRICAN AMERICAN A BLACK OR AFRICAN AMERICANA . . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWY .. DdD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWY. Normal weightA NNYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081817100818171008AYEARSFA ASIAN A@NOT HISPANIC OR LATINOA OTHER C>pUSAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23413 DVDDW.DWDVDVDDWDHDVDDWDנDWDDWDHHrHHs HrHHr̠HsnfHs DVDWDWDWAYEARSAYEARS12-15 YearsAASIAN A@ALL OTHERS A0. . Placebo AYY Y NY YDWVBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDנ.DDH.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW3DWDWDWDX`NEG....YNNNNYNDV........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBB~BpBrC0B8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081818100818181008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23415 DVDިDW.DWDVDVDިDWDpDVDިDWDp....Hr(HrcpHr(Hrcp..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWN .. DިDp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWN. Underweight ANYYYNEGDW,DWDW..NEG....YNNNNYYDV........DW,DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNYYNYDWDWDWBB|BrC0B8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081819100818191008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23418 DVDpDW.DWDVDVDpDWD DVDpDWD,DWDDWD HrlpHs/HrlpHr_Hss{Hs/DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWYBNT162b2 (30 (*ESC*){unicode 03BC}g).. DpD,.DD .424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW/DWDWDWDXdNEG....YNNNNYNDV........DW/.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBlBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081820100818201008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23629 DVDDW.DWDVDVDDWDDVDDWDDWD0DWDHrmHsHrmHrHHs|HsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWNBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.D0D.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDWDXkNEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBeBrCB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081821100818211008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23634 DVDDW.DWDVDVDDWDӤDVDDWDӤ....HruHrͱHruHrͱ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWK .. DDӤ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWK. Underweight ANNYYNEGDW/DWDW..NEG....YNNNNYYDV........DW/DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081822100818221008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23635 DVDDW.DWDVDVDDWD4DVDDWDDWDDWD4HrxHsHrxHrb|HsncHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWcBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDWDX`NEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBpBrCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081823100818231008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23636 DVDDW.DWDVDVDDWD}dDVDDWD}d....HrzHr HrzHr ..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWR .. DD}d....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWR. Normal weightA NNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBByBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081824100818241008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23654 DVD<DW.DWDVDVD<DWDDVD<DWD....Hr<HrHr<Hr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWS .. D<D....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWS. Underweight ANNYYNEGDW3DWDW..NEG....YNNNNYYDV........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBByBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081825100818251008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23656 DVDƄDW.DWDVDVDƄDWD4DVDƄDWDDWDxDWD4HrHs4HrHrMdHsm&Hs4DVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo ANY Y NY Y.BNT162b2 (30 (*ESC*){unicode 03BC}g).. DƄD.DxD4.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW2DWDWDWDX_NEG....YNNNNYNDV........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBqBrCB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081826100818261008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23659 DVDDW.DWDVDVDDWD|DVDDWD|....HrHr͝|HrHr͝|..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWZ .. DD|....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWZ. Normal weightA NNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081827100818271008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23821 DVDԔDW.DWDVDVDԔDWDDVDԔDWD....HrHr]HrHr]..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DԔD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Underweight ANNNYPOSDW3DWDW..POS....YNNNNYYDV........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NNDWDWDWBByBrCB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081828100818281008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23660 DVDDW.DWDVDVDDWD,DVDDWDlDWD\DWD,HrHsnHrHrlHsnX\HsnDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW@BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDl.D\D,.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW@DWDWDWDXdNEG....YNNNNYNDV........DW@.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBnBpBrCB8-9 months A3-4 months A@4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081829100818291008AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV23824 DVDDW.DWDVDVDDWD DVDDWD ....Hr0Hrͳ Hr0Hrͳ ..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0DWWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Underweight ANNYYNEGDW0DWDW..NEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBzBxA BB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1008 10081830100818301008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23825 DVDDW.DWDVDVDDWDDVDDWDPDWDDWDHrHsHrHrHsupHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDP.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW1DWDWDWDXeNEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBwBkBrBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081831100818311008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23827 DVDhDW.DWDVDVDhDWD{DVDhDWD{....HrHrYHrHrY..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDW: .. DhD{....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDW:. Overweight A0NNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081832100818321008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23986 DVDDW.DWDVDVDDWDDVDDWD....HrʘHr`HrʘHr`..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWM .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWM. Obese A@YNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBsBwBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081833100818331008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV23988 DVDDW.DWDVDVDDWD$DVDDWDDWDDWD$HrlHsHrlHr`HsnoHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWMBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DD$.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW0DWDWDWDX`NEG....YNNNNYNDV........DW0.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBxBpBrBB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081834100818341008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo A .Placebo A .Placebo Placebo (b)(6) . DV23991 DVDxDW.DWDVDVDxDWDDVDxDWD....HrHrHrHr..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE ADWWITHDRAWAL BY PARENT/GUARDIAN . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DxD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo DW.. Normal weightA NNYYNEGDW1DWDW..NEG....YNNNNYNDV........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWByBwA BB4-5 months AP4-5 months AP0-1 month A5-6 months A` . ...C4591001C4591001 1008 10081835100818351008AYEARSMAASIAN A@NOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV23993 DVDDW.DWDVDVDDWDxDVDDWDx....HrHrͰxHrHrͰx..DVDW..AYEARS. 12-15 YearsAASIAN A@ALL OTHERS A0. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWY .. DDx....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWY. Normal weightA NNYYNEGDW0DWDW..NEG....YNNNNYYDV........DW0DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081836100818361008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24088 DVDҴDW.DWDVDVDҴDWDxDVDҴDWD}(DWDDWDxHr4HsHr4Hr[(HsnKHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWEBNT162b2 (30 (*ESC*){unicode 03BC}g).. DҴD}(.DDx.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW2DWDWDWDX`NEG....YNNNNYNDV........DW2.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBxBpBrBB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081837100818371008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DV24089 DVDPDW.DWDVDVDPDWDDVDPDWDDDWDDWDHr HsHr HrͷDHsuPHsDVDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWOBNT162b2 (30 (*ESC*){unicode 03BC}g).. DPDD.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW3DWDWDWDXeNEG....YNNNNYNDV........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBxBkBrBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081838100818381008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV24090 DVD@DW.DWDVDVD@DWDTDVD@DWDT....Hr HrͶTHr HrͶT..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWO .. D@DT....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWO. Overweight A0NNYYNEGDW3DWDW..NEG....YNNNNYYDV........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081839100818391008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DV24091 DVDިDW.DWDVDVDިDWDpDVDިDWDp....Hr (HrͩpHr (Hrͩp..DVDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWT .. DިDp....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWT. Normal weightA NNYYNEGDW6DWDW..NEG....YNNNNYYDV........DW6DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBxBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081840100818401008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24193 DWDDW.DWDWDWDDWDDWDDWDҴDWDӤDWDHrHs'HrHr4HsnHs'DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWTBNT162b2 (30 (*ESC*){unicode 03BC}g).. DDҴ.DӤD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDWDX`NEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBwBpBrBB8-9 months A4-5 months AP4-5 monthsAP9-10 months A . ...C4591001C4591001 1008 10081841100818411008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24195 DWDDW.DWDWDWDDWDDWDDWD....HrHrxHrHrx..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)ANY Y NY Y. .. DD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DW.. Normal weightA NNYYNEGDW3DWDW..NEG....YNNNNYYDW........DW3DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBwBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081842100818421008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24196 DWDDW.DWDWDWDDWDDWDDWDyDWDDWDHr HsHr HrWHsu HsDWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDW:BNT162b2 (30 (*ESC*){unicode 03BC}g).. DDy.DD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Underweight ANNYYNEGDW:DWDWDWDXePOS....YNNNNYNDW........DW:.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NNDWDWDWBBxBkBrBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ..DWC4591001C4591001 1008 10081843100818431008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24198 DWDDW.DWDWDWDDWDӤDWDDWDӤ....HrHr$HrHr$..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWg .. DDӤ....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWg. Normal weightA NYYYNEGDW1DWDW..NEG....YNNNNYYDW........DW1DWYY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YYNNNY NYDWDWDWBBwBrBB8-9 months A4-5 months AP0-1 month A9-10 months A . ...C4591001C4591001 1008 10081844100818441008AYEARSMAWHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24201 DWDDW.DWDWDWDDWD(DWDDWDDWDDDWD(HrHs(HrHr`HstHs(DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. DD.DDD(.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW1DWDWDWDXeNEG....YNNNNYNDW........DW1.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBBwBkBrBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081845100818451008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY Placebo PLACEBO Placebo PLACEBO Placebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo ABNT162b2 Phase 2/3 (30 mcg)APlacebo => BNT162b2 Phase 2/3 (30 mcg)Placebo => BNT162b2 Phase 2/3 (30 mcg)(b)(6) . DW24207 DWD4DW.DWDWDWD4DWDDWD4DWD|DWDXDWDHr4Hs3Hr4HrHsrnHs3DWDWDWDWAYEARSAYEARS12-15 YearsAWHITE AWHITE A. . Placebo AYY Y NY YDWgBNT162b2 (30 (*ESC*){unicode 03BC}g).. D4D|.DXD.424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .Placebo Placebo BNT162b2 (30 (*ESC*){unicode 03BC}g)DWDW. Normal weightA NNYYNEGDW3DWDWDWDXdNEG....YNNNNYNDW........DW3.YY YYNY Ydid not have at least 1 valid and determinate immunogenicity result after Dose 2did not have at least 1 valid and determinate immunogenicity result within 28-42 days after Dose 2 NYYYYYN YNNYNY NYDWDWDWBByBmBrBB8-9 months A4-5 months AP3-4 monthsA@9-10 months A . ...C4591001C4591001 1008 10081846100818461008AYEARSFA WHITE ANOT HISPANIC OR LATINOA .USAYYY BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)B2_P23_30BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg)A .BNT162b2 Phase 2/3 (30 mcg) BNT162b2 Phase 2/3 (30 mcg) (b)(6) . DW24212 DWDPDW.DWDWDWDPDWDDWDPDWD....Hr PHrHHr PHrH..DWDW..AYEARS. 12-15 YearsAWHITE AWHITE A. . BNT162b2 Phase 2/3 (30 mcg)AYY Y NY YDWg .. DPD....424439 Jennings, Timothy W. ..Y .A@Phase 3<65 Years 12-15 YearsAA. .BNT162b2 (30 (*ESC*){unicode 03BC}g)BNT162b2 (30 (*ESC*){unicode 03BC}g) DWDWg. Normal weightA NNYYNEGDW3DWDW..NEG....YNNNNYYDW